<SEC-DOCUMENT>0001193125-25-022833.txt : 20250210
<SEC-HEADER>0001193125-25-022833.hdr.sgml : 20250210
<ACCEPTANCE-DATETIME>20250207181251
ACCESSION NUMBER:		0001193125-25-022833
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20250207
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250210
DATE AS OF CHANGE:		20250207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Neuronetics, Inc.
		CENTRAL INDEX KEY:			0001227636
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38546
		FILM NUMBER:		25603134

	BUSINESS ADDRESS:	
		STREET 1:		3222 PHOENIXVILLE PIKE
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
		BUSINESS PHONE:		877-600-7555

	MAIL ADDRESS:	
		STREET 1:		3222 PHOENIXVILLE PIKE
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NEURONETICS INC
		DATE OF NAME CHANGE:	20030416
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d928209d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stim="http://www.neurostar.com/20250207" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-325">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-02-07_to_2025-02-07">0001227636</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="stim-20250207.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-02-07_to_2025-02-07"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001227636</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-02-07</xbrli:startDate> <xbrli:endDate>2025-02-07</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-336">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported) <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-02-07_to_2025-02-07" format="ixt:datemonthdayyearen" id="ixv-337">February&#160;7, 2025</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-338">NEURONETICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-02-07_to_2025-02-07" format="ixt-sec:stateprovnameen" id="ixv-339">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-340">001-38546</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-341">33-1051425</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(State or other jurisdiction<br/>of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Commission<br/>File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-342">3222 Phoenixville Pike</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-343">Malvern</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-344">PA</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-345">19355</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-346">(610)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-347">640-4202</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report.) Not applicable.</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-02-07_to_2025-02-07" format="ixt-sec:boolballotbox" id="ixv-348">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-02-07_to_2025-02-07" format="ixt-sec:boolballotbox" id="ixv-349">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-02-07_to_2025-02-07" format="ixt-sec:boolballotbox" id="ixv-350">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-02-07_to_2025-02-07" format="ixt-sec:boolballotbox" id="ixv-351">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol (s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name on each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-352">Common Stock ($0.01 par value)</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-353">STIM</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-02-07_to_2025-02-07" format="ixt-sec:exchnameen" id="ixv-354">The Nasdaq Global Market</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934.</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-02-07_to_2025-02-07" format="ixt-sec:boolballotbox" id="ixv-355">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;7, 2025, Neuronetics, Inc. (the &#8220;Company&#8221;) entered into an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Canaccord Genuity LLC, as representative of the underwriters named in Schedule&#160;I attached thereto (the &#8220;Underwriter&#8221;), pursuant to which the Company agreed to issue and sell 8,000,000 shares (the &#8220;Firm Shares&#8221;) of the Company&#8217;s common stock, par value $0.01 per share (&#8220;Common Stock&#8221;), at a price to the public of $2.25 per share (the &#8220;Offering&#8221;). Under the terms of the Underwriting Agreement, the Company granted the Underwriter an option, exercisable in whole or in part, at any time for a period of 30 days from the date of the Underwriting Agreement, to purchase an additional 1,200,000 shares of Common Stock (the &#8220;Option Shares,&#8221; and together with the Firm Shares, the &#8220;Shares&#8221;) at the public offering price. The Company expects the Offering to close on February&#160;10, 2025, subject to the satisfaction of customary closing conditions. All Shares in the Offering are being sold by the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimates that the net proceeds to the Company from the Offering, after deducting underwriting discounts and commissions and estimated offering expenses, will be approximately $16.355&#160;million (or $18.893&#160;million including the Option Shares). The Company expects to use the net proceeds from the Offering for general corporate purposes, including but not limited to sales and marketing, research and development activities, financing of potential acquisitions or establishment of healthcare practices, purchases of inventory, general and administrative matters, working capital and capital expenditures. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February 7, the Underwriter notified the Company of its exercise of the option to purchase the full amount of the Option Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offering is being made pursuant to a prospectus supplement, dated February&#160;7, 2025 (the &#8220;Prospectus Supplement&#8221;), filed with the SEC on February&#160;7, 2025 and an accompanying base prospectus that forms a part of the registration statement on Form <span style="white-space:nowrap">S-3,</span> as amended (File <span style="white-space:nowrap">No.&#160;333-266617),</span> declared effective on November&#160;14, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties and covenants of the Company and also provides for customary indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates and were solely for the benefit of the parties to such agreement. The foregoing description of the Underwriting Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Underwriting Agreement, which is filed as Exhibit 1.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated by reference herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the legal opinion of Ballard Spahr LLP, relating to the legality of the issuance and sale of the Shares in the Offering, is filed as Exhibit 5.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated by reference herein. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;6, 2025, the Company issued a press release announcing the launch of the Offering, and on February&#160;7, 2025, the Company issued a press release announcing the pricing of the Offering. Copies of the press releases are attached as Exhibits 99.1 and 99.2 hereto, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cautionary Note Regarding Forward Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report <span style="white-space:nowrap">on&#160;Form&#160;8-K&#160;contains</span> forward-looking statements that involve estimates, assumptions, risks and uncertainties. Forward-looking statements include, but are not limited to, statements related to the amount of proceeds expected from the Offering, the timing and certainty of completion of the Offering and the anticipated use of proceeds from the Offering. The risks and uncertainties relating to the Company and the Offering include general market conditions, the Company&#8217;s ability to complete the Offering on favorable terms, or at all, as well as other risks detailed from time to time in the Company&#8217;s filings with the SEC, including in its Annual Report <span style="white-space:nowrap">on&#160;Form&#160;10-K&#160;for</span> the year ended December&#160;31, 2023 and in its Quarterly Report <span style="white-space:nowrap">on&#160;Form&#160;10-Q&#160;for</span> the quarter ended September&#160;30, 2024 and the Prospectus Supplement. These documents contain important factors that could cause actual results to differ from current expectations and from the forward-looking statements contained in this Current Report <span style="white-space:nowrap">on&#160;Form&#160;8-K.&#160;These</span> forward-looking statements speak only as of the date of this Current Report on&#160;Form&#160;8-K and the Company undertakes no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this Current Report <span style="white-space:nowrap">on&#160;Form&#160;8-K.</span> </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <span style="text-decoration:underline">Exhibits</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br/>Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d928209dex11.htm">Underwriting Agreement, dated as of February&#160;7, 2025, by and between Neuronetics, Inc. and Canaccord Genuity LLC </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d928209dex51.htm">Opinion of Ballard Spahr LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d928209dex51.htm">Consent of Ballard Spahr LLP (contained in Exhibit&#160;5.1 above) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d928209dex991.htm">Press release issued by Neuronetics, Inc. on February&#160;6, 2025 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d928209dex992.htm">Press release issued by Neuronetics, Inc. on February&#160;7, 2025 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">NEURONETICS, INC.</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">(Registrant)</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: February&#160;7, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen Furlong</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Stephen Furlong</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">EVP, Chief Financial Officer and Treasurer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d928209dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Execution Version</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>8,000,000 Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEURONETICS, INC. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Common
Stock, $0.01 par value per share </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDERWRITING AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">February&nbsp;7, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CANACCORD GENUITY LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As Representative of the several </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Underwriters named in Schedule&nbsp;I hereto </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Canaccord Genuity LLC </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One Post Office Square, Suite 3000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Boston, MA 02109 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neuronetics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;) proposes to sell to the several Underwriters named in
Schedule&nbsp;I hereto (the &#147;<B><I>Underwriters</I></B>&#148;) an aggregate of 8,000,000 shares (the &#147;<B><I>Firm Shares</I></B>&#148;) of common stock, $0.01 par value per share (the &#147;<B><I>Common Stock</I></B>&#148;), of the Company.
The Firm Shares consist of 8,000,000 authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to 1,200,000 additional shares of Common
Stock on the terms and for the purposes set forth in Section&nbsp;3 hereof (the &#147;<B><I>Option Shares</I></B>&#148;). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this
&#147;<B><I>Agreement</I></B>&#148;) are herein collectively called the &#147;<B><I>Securities</I></B>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms
its agreement with respect to the sale of the Securities to the several Underwriters, for whom Canaccord Genuity LLC is acting as representative (the &#147;<B><I>Representative</I></B>&#148; and if there are no Underwriters other than Canaccord
Genuity LLC, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B><I>Registration Statement and Prospectus</I></B>. The Company has prepared and filed with the Securities and Exchange Commission (the
&#147;<B><I>Commission</I></B>&#148;) a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> as amended (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-266617),</FONT> under the Securities Act of 1933, as amended (the
&#147;<B><I>Securities Act</I></B>&#148; or &#147;<B><I>Act</I></B>&#148;) and the rules and regulations (the &#147;<B><I>Rules and Regulations</I></B>&#148;) of the Commission thereunder, and such amendments to such registration statement as may
have been required to the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such registration statement has been declared effective by the Commission. Each part of
such registration statement, including the amendments, exhibits and any schedules thereto, the documents incorporated by reference therein pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act and the
documents and information otherwise deemed to be a part thereof or included therein by Rule 430B under the Securities Act (the &#147;<B><I>Rule 430B Information</I></B>&#148;) or otherwise pursuant to the Rules and Regulations, as of the time the
Registration Statement became effective, is herein called the &#147;<B><I>Registration Statement</I></B>.&#148; Any registration statement filed by the Company pursuant to Rule 462(b) under the Securities Act is called the &#147;Rule 462(b)
Registration Statement&#148; and, from and after the date and time of filing of the Rule 462(b) Registration Statement, the term &#147;Registration Statement&#148; shall include the Rule 462(b) Registration Statement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus in the form in which it has most recently been filed with the Commission on
or prior to the date of this Agreement is herein called the &#147;<B><I>Base Prospectus</I></B>.&#148; Each preliminary prospectus supplement to the Base Prospectus (including the Base Prospectus as so supplemented), that describes the Securities
and the offering thereof, that omitted the Rule 430B Information and that was used prior to the filing of the final prospectus supplement referred to in the following sentence is herein called a &#147;<B><I>Preliminary Prospectus</I></B>.&#148;
Promptly after execution and delivery of this Agreement, the Company will prepare and file with the Commission a final prospectus supplement to the Base Prospectus relating to the Securities and the offering thereof in accordance with the provisions
Rule 430B and Rule 424(b) of the Rules and Regulations. Such final supplemental form of prospectus (including the Base Prospectus as so supplemented), in the form filed with the Commission pursuant to Rule 424(b) is herein called the
&#147;<B><I>Prospectus</I></B>.&#148; Any reference herein to the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to include the documents incorporated by reference therein pursuant to Item 12 of Form <FONT
STYLE="white-space:nowrap">S-3</FONT> under the Securities Act as of the date of such prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, all
references to the Registration Statement, the Rule&nbsp;462(b) Registration Statement, the Base Prospectus, any Preliminary Prospectus, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed
with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System or any successor system thereto (&#147;<B><I>EDGAR</I></B>&#148;). All references in this Agreement to financial statements and schedules and other
information which is &#147;described,&#148; &#147;contained,&#148; &#147;included&#148; or &#147;stated&#148; in the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Prospectus (or other references of like import) shall
be deemed to mean and include all such financial statements and schedules and other information which is incorporated by reference in or otherwise deemed by the Rules and Regulations to be a part of or included in the Registration Statement, the
Base Prospectus, any Preliminary Prospectus or the Prospectus, as the case may be; and all references in this Agreement to amendments or supplements to the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Prospectus
shall be deemed to mean and include the subsequent filing of any document under the Securities Exchange Act of 1934, as amended (the &#147;<B><I>Exchange Act</I></B>&#148;) and which is deemed to be incorporated therein by reference therein or
otherwise deemed by the Rules and Regulations to be a part thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B><I>Representations and Warranties of the Company</I></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I><U>Representations and Warranties of the Company</U></I>. The Company represents and warrants to, and agrees with, the several
Underwriters as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U><I>Registration Statement and Prospectuses</I></U>. No order preventing or suspending the
use of any Preliminary Prospectus or the Prospectus (or any supplement thereto) has been issued by the Commission and no proceeding for that purpose has been initiated or is pending or, to the knowledge of the Company, threatened by the Commission.
As of the time each part of the Registration Statement (or any post-effective amendment thereto) became or becomes effective (including each deemed effective date with respect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
to the Underwriters pursuant to Rule 430B or otherwise under the Securities Act), such part conformed or will conform in all material respects to the requirements of the Act and the Rules and
Regulations. Upon the filing or first use within the meaning of the Rules and Regulations, each Preliminary Prospectus and the Prospectus (or any supplement to either) conformed or will conform in all material respects to the requirements of the Act
and the Rules and Regulations. The Registration Statement and any post-effective amendment thereto has become effective under the Securities Act within three years of the date hereof. The Company has complied to the Commission&#146;s satisfaction
with all requests of the Commission for additional or supplemental information. No stop order suspending the effectiveness of the Registration Statement, any post-effective amendment or any part thereof is in effect and no proceedings for such
purpose have been instituted or are pending or, to the knowledge of the Company, are threatened by the Commission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)
<U><I>Accurate Disclosure</I></U>. Each Preliminary Prospectus, at the time of filing thereof or the time of first use within the meaning of the Rules and Regulations, did not contain an untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. Neither the Registration Statement nor any amendment thereto, at the effective
time of each part thereof, at the First Closing Date (as defined below) or at the Second Closing Date (as defined below), contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material
fact required to be stated therein or necessary to make the statements therein not misleading. As of the Time of Sale (as defined below), neither (A)&nbsp;the Time of Sale Disclosure Package (as defined below) nor (B)&nbsp;any issuer free writing
prospectus (as defined below), when considered together with the Time of Sale Disclosure Package, included an untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading. Neither the Prospectus nor any supplement thereto, as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b) of the Rules and Regulations, at the First
Closing Date or Second Closing Date, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. The representations and warranties in this Section&nbsp;2(a)(ii) shall not apply to statements in or omissions from any Preliminary Prospectus, the Registration Statement (or any amendment thereto), the
Time of Sale Disclosure Package or the Prospectus (or any supplement thereto) made in reliance upon, and in conformity with, written information furnished to the Company by you, or by any Underwriter through you, specifically for use in the
preparation of such document, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;6(f). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each reference to an &#147;<B><I>issuer free writing prospectus</I></B>&#148; herein means an issuer free writing prospectus as defined in Rule 433 of the
Rules and Regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Time of Sale Disclosure Package</I></B>&#148; means the Preliminary Prospectus dated February&nbsp;6, 2025, any free
writing prospectus set forth on Schedule II and the information on Schedule III, all considered together. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each reference to a &#147;<B><I>free writing prospectus</I></B>&#148; herein means a free writing prospectus
as defined in Rule 405 of the Rules and Regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Time of Sale</I></B>&#148; means 7:00 a.m. (Eastern time) on the date of this Agreement.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) <U><I>Issuer Free Writing Prospectuses</I></U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;Each Issuer Free Writing Prospectus does not include any information that conflicts with the information contained in
the Registration Statement, any Preliminary Prospectus or the Prospectus. The foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus based upon and in conformity with written information furnished to
the Company by you or by any Underwriter through you specifically for use therein; it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;6(f). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(B) (1) At the earliest time after the filing of the Registration Statement that the Company or another offering participant
made a bona fide offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Securities and (2)&nbsp;at the date hereof, the Company was not and is not (as applicable) an &#147;ineligible issuer,&#148; as defined in Rule 405 under
the Securities Act, including the Company or any Subsidiary (as defined below) in the preceding three years not having been convicted of a felony or misdemeanor or having been made the subject of a judicial or administrative decree or order as
described in Rule 405 of the Rules and Regulations (without taking account of any determination by the Commission pursuant to Rule 405 of the Rules and Regulations that it is not necessary that the Company be considered an ineligible issuer), nor an
&#147;excluded issuer&#148; as defined in Rule 164 under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(C) Each Issuer Free Writing Prospectus
satisfied, as of its issue date and at all subsequent times to the Time of Sale, all other conditions to use thereof as set forth in Rules 164 and 433 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) <U><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Materials</I></U>. The Company (i)&nbsp;has not alone engaged in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications (as defined below), other than <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the prior consent of the Representative with entities that are qualified institutional buyers within the meaning of Rule 144A under the Act or institutions that are
accredited investors within the meaning of Rule 501 under the Act and (ii)&nbsp;has not authorized anyone other than the Representative to engage in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communications. The Company reconfirms that the Representative has been authorized to act on its behalf in undertaking <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company has
not distributed any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications (as defined below) other than those listed on Schedule V hereto.
&#147;<B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication</I></B>&#148; means any oral or written communication with potential investors undertaken in reliance on Rule 163B under the
Act. &#147;<B><I>Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication</I></B>&#148; means any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the Act. Any individual Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication does not conflict with the information contained in the Registration Statement or the Time of Sale Disclosure Package, complied in all material
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
respects with the Act, and when taken together with the Time of Sale Disclosure Package as of the Time of Sale, did not contain any untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) <U><I>No Other Offering Materials</I></U>. The Company has not distributed and will not distribute any prospectus or other
offering material in connection with the offering and sale of the Securities other than any Preliminary Prospectus, the Time of Sale Disclosure Package or the Prospectus or other materials permitted by the Act to be distributed by the Company;
<I>provided</I>, <I>however</I>, that, except as set forth on Schedule II, the Company has not made and will not make any offer relating to the Securities that would constitute a free writing prospectus, except in accordance with the provisions of
Section&nbsp;4(a)(xv) of this Agreement and, except as set forth on Schedule&nbsp;V, the Company has not made and will not make any communication relating to the Securities that would constitute a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, except in accordance with the provisions of Section&nbsp;2(a)(iv) of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) <U><I>Financial Statements</I></U>. The financial statements of the Company, together with the related notes, set forth or
incorporated by reference in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus comply in all material respects with the requirements of the Securities Act and the Exchange Act and fairly present, in all material
respects, the financial condition of the Company as of the dates indicated and the results of operations and changes in cash flows for the periods therein specified in conformity with generally accepted accounting principles in the United States
(&#147;<B><I>GAAP</I></B>&#148;) consistently applied throughout the periods involved; the supporting schedules included in the Registration Statement present fairly the information required to be stated therein; all
<FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial information included in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus complies in all material respects with the requirements of Regulation G and Item 10
of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Act; and, except as disclosed in the Time of Sale Disclosure Package and the Prospectus, there are no material <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements
(as defined in Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Act, Item 303(a)(4)(ii)) or other relationships with unconsolidated entities or other persons that are reasonably likely to have a material effect on the Company&#146;s
financial condition, results of operations, liquidity, capital expenditures, capital resources or significant components of revenue or expenses. Except as included or incorporated by reference therein, no historical or pro forma financial statements
or supporting schedules are required to be included or incorporated by reference in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus under the Securities Act or the rules and regulations promulgated thereunder. The
pro forma consolidated financial statements of the Company and its Subsidiaries and the related notes thereto included in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus present fairly, in all material respects,
the information contained therein, have been prepared in accordance with the Commission&#146;s rules and guidelines with respect to pro forma financial statements and have been properly presented on the bases described therein, and the assumptions
used in the preparation thereof are reasonable and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein. No other financial statements or schedules are required to be included in the
Registration Statement, the Time of Sale </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Disclosure Package or the Prospectus. KPMG LLP, which has expressed its opinions with respect to the financial statements and schedules of the Company filed as a part of the Registration
Statement and included in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, is (x)&nbsp;an independent public accounting firm within the meaning of the Act and the Rules and Regulations, (y)&nbsp;a registered public
accounting firm (as defined in Section&nbsp;2(a)(12) of the Sarbanes-Oxley Act of 2002 (the &#147;<B><I>Sarbanes-Oxley Act</I></B>&#148;)) and (z)&nbsp;not in violation of the auditor independence requirements of the Sarbanes-Oxley Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) <U><I>Organization and Good Standing</I></U>. The Company and each &#147;significant subsidiary&#148; of the Company (as
such term is defined in Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X)</FONT> (each, a &#147;<B><I>Subsidiary</I></B>&#148; and, collectively, the &#147;<B><I>Subsidiaries</I></B>&#148;) has
been duly organized and is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation or organization. The Company and each of its Subsidiary has full corporate power and authority to own its
properties and conduct its business as currently being carried on and as described in the Registration Statement, the Time of Sale Disclosure Package and Prospectus, and is duly qualified to do business as a foreign corporation in good standing in
each jurisdiction in which it owns or leases real property or in which the conduct of its business makes such qualification necessary and in which the failure to so qualify would individually, or in the aggregate, result in a Material Adverse
Effect. &#147;<B><I>Material Adverse Effect</I></B>&#148; shall mean any material adverse change or effect, or any development involving a prospective material adverse change or effect, in or affecting (i)&nbsp;the business, earnings, assets,
liabilities, prospects, properties, condition (financial or otherwise), operations, general affairs, management, financial position, stockholders&#146; equity or results of operations of the Company and its Subsidiaries, taken as a whole or
(ii)&nbsp;the ability of the Company to perform its obligations under this Agreement, including the issuance and sale of the Securities, or to consummate the transactions contemplated in the Time of Sale Disclosure Package and the Prospectus </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) <U><I>Absence of Certain Events</I></U>. Except as contemplated in the Time of Sale Disclosure Package and in the
Prospectus, subsequent to the date as of which information is given in the Time of Sale Disclosure Package, neither the Company nor any of its Subsidiaries has incurred any material liabilities or obligations, direct or contingent, or entered into
any material transactions, in each of the foregoing cases, taken as a whole, or declared or paid any dividends or made any distribution of any kind with respect to its capital stock; and there has not been any change in the capital stock (other than
a change in the number of outstanding shares of Common Stock due to the issuance of shares upon the exercise of outstanding options or warrants or conversion of convertible securities), or any material change in the short-term or long-term debt
(other than as a result of the conversion of convertible securities), or any issuance of options, warrants, convertible securities or other rights to purchase the capital stock of the Company or any of its Subsidiaries, or any Material Adverse
Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) <U><I>Absence of Proceedings</I></U>. Except as set forth in the Time of Sale Disclosure Package and in the
Prospectus, there is not pending or, to the knowledge of the Company, threatened or contemplated, any action, suit or proceeding (a)&nbsp;to which the Company or any of its Subsidiaries is a party or (b)&nbsp;which has as the subject thereof any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
officer or director of the Company or any of its Subsidiaries, any employee benefit plan sponsored by the Company or any of its Subsidiaries or any property or assets owned or leased by the
Company or any of its Subsidiaries before or by any court or Governmental Authority (as defined below), or any arbitrator, which, individually or in the aggregate, would reasonably be expected to result in any Material Adverse Effect. There are no
current or, to the knowledge of the Company, pending, legal, governmental or regulatory actions, suits or proceedings (x)&nbsp;to which the Company or any of its Subsidiaries is subject or (y)&nbsp;which has as the subject thereof any officer or
director of the Company or any of its Subsidiaries, any employee plan sponsored by the Company or any of its Subsidiaries or any property or assets owned or leased by the Company or any of its Subsidiaries, that are required to be described in the
Registration Statement, the Time of Sale Disclosure Package and the Prospectus by the Act or by the Rules and Regulations and that have not been so described. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) <U><I>Authorization; No Conflicts; Authority</I></U>. This Agreement has been duly authorized, executed and delivered by
the Company, and constitutes a valid, legal and binding obligation of the Company, enforceable in accordance with its terms, except as rights to indemnity hereunder may be limited by federal or state securities laws and except as such enforceability
may be limited by bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally and subject to general principles of equity. The execution, delivery and performance of this Agreement and the consummation of the
transactions herein contemplated will not (A)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon
any property or assets of the Company or any of its Subsidiaries pursuant to any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its Subsidiaries is a party or by which the Company
or any of its Subsidiaries is bound or to which any of the property or assets of the Company is subject, (B)&nbsp;result in any violation of the provisions of the Company&#146;s charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or
(C)&nbsp;result in the violation of any law or statute or any judgment, order, rule, regulation or decree of any court or arbitrator or federal, state, local or foreign governmental agency or regulatory authority having jurisdiction over the Company
or any of its Subsidiaries or any of their properties or assets (each, a &#147;<B><I>Governmental Authority</I></B>&#148;), except in the case of clauses (A)&nbsp;and (C)&nbsp;as would not reasonably be expected to result in a Material Adverse
Effect. No consent, approval, authorization or order of, or registration or filing with any Governmental Authority is required for the execution, delivery and performance of this Agreement or for the consummation of the transactions contemplated
hereby, including the issuance or sale of the Securities by the Company, except such as may be required under the Act, the rules of the Financial Industry Regulatory Authority (&#147;<B><I>FINRA</I></B>&#148;) or state securities or blue sky laws;
and the Company has full power and authority to enter into this Agreement and to consummate the transactions contemplated hereby, including the authorization, issuance and sale of the Securities as contemplated by this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi) <U><I>Capitalization; the Securities; Registration Rights</I></U>. All of the issued and outstanding shares of capital
stock of the Company, including the outstanding shares of Common Stock, have been duly authorized and validly issued and are fully paid and nonassessable, have been issued in compliance with all applicable federal and state and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
foreign securities laws, were not issued in violation of any preemptive rights or other rights to subscribe for or purchase securities that have not been waived in writing (a copy of which has
been delivered to counsel to the Representative), and the holders thereof are not subject to personal liability by reason of being such holders; the Securities which may be sold hereunder by the Company have been duly authorized and, when issued,
delivered and paid for in accordance with the terms of this Agreement, will be validly issued, fully paid and nonassessable, and the holders thereof will not be subject to personal liability by reason of being such holders; and the capital stock of
the Company, including the Common Stock, conforms in all material respects to the description thereof in the Registration Statement, in the Time of Sale Disclosure Package and in the Prospectus. Except as otherwise stated in the Registration
Statement, in the Time of Sale Disclosure Package and in the Prospectus, (A)&nbsp;there are no preemptive rights or other rights to subscribe for or to purchase, or any restriction upon the voting or transfer of, any shares of Common Stock pursuant
to the Company&#146;s charter, <FONT STYLE="white-space:nowrap">by-laws</FONT> or any agreement or other instrument to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound,
(B)&nbsp;neither the filing of the Registration Statement nor the offering or sale of the Securities as contemplated by this Agreement gives rise to any rights for or relating to the registration of any shares of Common Stock or other securities of
the Company or its Subsidiaries (collectively &#147;<B><I>Registration Rights</I></B>&#148;) that have not been validly waived and (C)&nbsp;any person to whom the Company has granted Registration Rights has agreed not to exercise or has otherwise
waived such rights until after expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period (as defined below). The issued and outstanding shares of capital stock of each Subsidiary owned by the Company, directly or indirectly, have been
duly and validly authorized and issued and are fully paid and nonassessable, and, except as otherwise described in the Registration Statement, in the Time of Sale Disclosure Package and in the Prospectus, the Company owns of record and beneficially,
free and clear of any security interests, claims, liens, proxies, equities or other encumbrances, all of the issued and outstanding shares of such stock. The Company has an authorized and outstanding capitalization as set forth in the Registration
Statement, in the Time of Sale Disclosure Package and in the Prospectus under the caption &#147;Capitalization.&#148; The Common Stock (including the Securities) conforms in all material respects to the description thereof contained in the Time of
Sale Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xii) <U><I>Equity Awards</I></U>. Except as described in the Registration
Statement, in the Time of Sale Disclosure Package and in the Prospectus, there are no options, restricted stock, restricted stock units, warrants, agreements, contracts or other rights or equity-based awards in existence to purchase or acquire from
the Company or any of its Subsidiaries any shares of the capital stock of the Company or any of its Subsidiaries. The description of the Company&#146;s equity incentive plans or arrangements (the &#147;<B><I>Company Equity Incentive
Plans</I></B>&#148;), and the options, restricted stock, restricted stock units or other rights or equity-based awards granted thereunder (the &#147;<B><I>Equity Awards</I></B>&#148;), set forth in the Time of Sale Disclosure Package and the
Prospectus accurately and fairly presents in all material respects the information required to be shown with respect to such Company Equity Incentive Plans and Equity Awards. Each grant of an Equity Award (A)&nbsp;was duly authorized no later than
the date on which the grant of such Equity Award was by its terms to be effective by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof)
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
and any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party
thereto, (B)&nbsp;was made in accordance with the terms of the applicable Company Equity Incentive Plan, and all applicable laws and regulatory rules or requirements, including all applicable federal securities laws and (C)&nbsp;was properly
accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company included in the Registration Statement, in the Time of Sale Disclosure Package and in the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiii) <U><I>Compliance with Laws</I></U>. The Company and each of its Subsidiaries holds, and is operating in compliance in
all material respects with, all franchises, grants, authorizations, licenses, permits, approvals, clearances, registrations, exemptions, easements, consents, certificates and orders of any Governmental Authority or self-regulatory body required for
the conduct of its business as currently conducted (collectively, &#147;<B><I>Permits</I></B>&#148;), including, without limitation, those Permits of the U.S. Food and Drug Administration (&#147;<B><I>FDA</I></B>&#148;), and all such Permits are
valid and in full force and effect; neither the Company nor any of its Subsidiaries have received notice of any revocation or modification of any such material Permit or has reason to believe that any such material Permit will not be renewed in the
ordinary course; and the Company and each of its Subsidiaries is in compliance in all material respects with all applicable federal, state, local and foreign laws, regulations, orders and decrees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiv) <U><I>Ownership of Assets</I></U>. The Company and each of its Subsidiaries have good and marketable title to all
property (whether real or personal) described in the Registration Statement, in the Time of Sale Disclosure Package and in the Prospectus as being owned by them, in each case free and clear of all liens, claims, security interests, other
encumbrances or defects except such as would not reasonably be expected to result in a Material Adverse Effect or as are described in the Registration Statement, in the Time of Sale Disclosure Package and in the Prospectus. The property held under
lease by the Company and each of its Subsidiaries is held by them under valid, subsisting and enforceable leases with only such exceptions with respect to any particular lease as do not interfere in any material respect with the conduct of the
business of the Company or any of its Subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xv) <U><I>Intellectual Property</I></U>. The Company and each of its
Subsidiaries own, possess, or has the right to use, all Intellectual Property necessary for the conduct of the Company&#146;s and each of its Subsidiaries business as now conducted or, as described in the Registration Statement, the Time of Sale
Disclosure Package and the Prospectus to be conducted, except as such failure to own, possess, or acquire have such rights would not result in a Material Adverse Effect. Furthermore, (A)&nbsp;to the knowledge of the Company, there is no
infringement, misappropriation or violation by third parties of any such Intellectual Property except as would not reasonably be expected to result in a Material Adverse Effect; (B)&nbsp;there is no pending or, to the knowledge of the Company,
threatened, action, suit, proceeding or claim by others challenging the Company&#146;s or any of its Subsidiaries&#146; ownership of or rights in or to any such Intellectual Property owned by the Company or Intellectual Property licensed by the
Company, and the Company is not aware of any facts that would form a reasonable basis for any such claim; (C)&nbsp;the Intellectual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Property owned by the Company and each of its Subsidiaries, and to the knowledge of the Company, the Intellectual Property licensed to the Company and each of its Subsidiaries, has not been
adjudged invalid or unenforceable, in whole or in part, and there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property, and the
Company is not aware of any facts that would form a reasonable basis for any such claim; (D)&nbsp;there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim that the Company or any of its Subsidiaries
infringes, misappropriates or otherwise violates any Intellectual Property or other proprietary rights of others, and neither the Company nor any of its Subsidiaries has received any written notice of such claim and is not aware of any facts that
would form a reasonable basis for any such claim; and (E)&nbsp;to the Company&#146;s knowledge, no employee of the Company or any of its Subsidiaries is in violation of any term of any employment contract, patent disclosure agreement, invention
assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the
basis of such violation relates to such employee&#146;s employment with the Company or any of its Subsidiaries or actions undertaken by the employee while employed with the Company or any of its Subsidiaries, except as such violation would not
result in a Material Adverse Effect. &#147;<B>Intellectual Property</B>&#148; shall mean all patents, patent applications, trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets,
domain names, technology, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property in the United States and foreign jurisdictions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvi) <U><I>No Violations or Defaults</I></U>. (A)&nbsp;The Company and each of its Subsidiaries is not in violation of their
respective organizational documents, or in breach of or otherwise in default, and (B)&nbsp;except as would not reasonably be expected to result in a Material Adverse Effect, no event has occurred which, with notice or lapse of time or both, would
constitute such a default in the performance of any material obligation, agreement or condition contained in any bond, debenture, note, indenture, loan agreement or any other material contract, lease or other instrument to which it is subject or by
which any of them may be bound, or to which any of the material property or assets of the Company or any of its Subsidiaries is subject. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvii) <U><I>Taxes</I></U>. The Company and each of its Subsidiaries have timely filed all federal, state, local and foreign
income and franchise tax returns required to be filed by it or has properly requested extensions thereof (except as such failure to timely file such tax returns would not result in a Material Adverse Effect) and is not in default in the payment of
any taxes which were payable pursuant to said returns or any assessments with respect thereto, other than any which the Company or any of its Subsidiaries is contesting in good faith by appropriate proceedings and for which adequate reserves have
been provided in accordance with GAAP, or as would not result in a Material Adverse Effect. There is no pending dispute with any taxing authority relating to any of such returns, and the Company has no knowledge of any proposed liability for any tax
to be imposed upon the properties or assets of the Company for which there is not an adequate reserve reflected in the Company&#146;s financial statements included in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus
except where such dispute or liability would not result in a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xviii) <U><I>Exchange Listing and Exchange Act Registration</I></U>. The
Common Stock is registered pursuant to Section&nbsp;12(b) of the Exchange Act and is included or approved for listing on the Nasdaq Global Market and the Company has taken no action designed to terminating the registration of the Common Stock under
the Exchange Act or delisting the Common Stock from the Nasdaq Global Market nor has the Company received any notification that the Commission or the Nasdaq Global Market is contemplating terminating such registration or listing. The Company has
complied in all material respects with the applicable requirements of the Nasdaq Global Market for maintenance of inclusion of the Common Stock thereon. Except as previously disclosed to counsel for the Underwriters or as set forth in the Time of
Sale Disclosure Package and the Prospectus, to the knowledge of the Company, no beneficial owners of the Company&#146;s capital stock or subordinated debt who, together with their associated persons and affiliates, hold in the aggregate 10% or more
of such capital stock or subordinated debt, have any direct or indirect association or affiliate with a FINRA member. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xix) <U><I>Internal Controls</I></U>. The Company and each of its Subsidiaries maintain a system of internal accounting
controls sufficient to provide reasonable assurances that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorization; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain accountability for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; and (iv)&nbsp;the recorded accountability for assets
is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;interactive data in eXtensible Business Reporting Language included or incorporated by reference in the
Registration Statement, the Prospectus and the Pricing Disclosure Package fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. Except as
disclosed in the Registration Statement, in the Time of Sale Disclosure Package and in the Prospectus, the Company&#146;s internal control over financial reporting is effective and none of the Company, its board of directors and audit committee is
aware of any &#147;significant deficiencies&#148; or &#147;material weaknesses&#148; (each as defined by the Public Company Accounting Oversight Board) in its internal control over financial reporting, or any fraud, whether or not material, that
involves management or other employees of the Company and each of its Subsidiaries who have a significant role in the Company&#146;s internal controls; and since the end of the latest audited fiscal year, there has been no change in the
Company&#146;s internal control over financial reporting (whether or not remediated) that has materially and adversely affected, or is reasonably likely to materially and adversely affect, the Company&#146;s internal control over financial
reporting. The Company&#146;s board of directors has, subject to the exceptions, cure periods and the phase in periods specified in the applicable stock exchange rules (&#147;<B><I>Exchange Rules</I></B>&#148;), validly appointed an audit committee
to oversee internal accounting controls whose composition satisfies the applicable requirements of the Exchange Rules and the Company&#146;s board of directors and/or the audit committee has adopted a charter that satisfies the requirements of the
Exchange Rules in respect of the Audit Committee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xx) <U><I>No Brokers or Finders</I></U>. Other than as contemplated by
this Agreement, the Company has not incurred and will not incur any liability for any finder&#146;s or broker&#146;s fee or agent&#146;s commission in connection with the execution and delivery of this Agreement or the consummation of the
transactions contemplated hereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxi) <U><I>Insurance</I></U>. The Company and each of its Subsidiaries
carry, or are covered by, insurance from reputable insurers in such amounts and covering such risks as the Company reasonably believes is adequate for the conduct of its business and the value of its properties and the properties of its Subsidiaries
and as is customary for companies engaged in similar businesses in similar industries; all policies of insurance and any fidelity or surety bonds insuring the Company or any of its Subsidiaries or their business, assets, employees, officers and
directors are in full force and effect; the Company and each of its Subsidiaries are in compliance with the terms of such policies and instruments in all material respects; there are no claims by the Company or any of its Subsidiaries under any such
policy or instrument as to which any insurance company is denying liability or defending under a reservation of rights clause; neither the Company nor any of its Subsidiaries have been refused any insurance coverage sought or applied for; and
neither the Company nor any of its Subsidiaries have reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to
continue its business at a cost that would not have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxii) <U><I>Investment Company
Act</I></U>. The Company is not, and after giving effect to the sale of the Securities in accordance with this Agreement and the application of proceeds as described in the Prospectus under the caption &#147;Use of Proceeds,&#148; will not be, an
&#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxiii)
<U><I>Eligibility to use Form <FONT STYLE="white-space:nowrap">S-3</FONT></I></U>. The Company meets the conditions for use of <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> to register the offer and sale of the Securities set forth in the
General Instructions thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxiv) <U><I>Incorporated Documents</I></U>. The documents incorporated by reference in the
Time of Sale Disclosure Package and in the Prospectus, when they became effective or were filed with the Commission, as the case may be, conformed in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable,
and were filed on a timely basis with the Commission and none of such documents contained an untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading; any further documents so filed and incorporated by reference in the Time of Sale Disclosure Package or in the Prospectus, when such documents are filed with the Commission, will conform in all material respects
to the requirements of the Exchange Act, and will not contain an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not
misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxv) <U><I>Sarbanes-Oxley Act</I></U>. The Company is in compliance with all applicable provisions of the
Sarbanes-Oxley Act and the rules and regulations of the Commission thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxvi) <U><I>Disclosure Controls</I></U>. The Company and each of its
Subsidiaries have established and maintains disclosure controls and procedures (as defined in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15&nbsp;and&nbsp;15d-15&nbsp;under</FONT></FONT> the Exchange Act) and
such controls and procedures are effective in ensuring that material information relating to the Company and each of its Subsidiaries is made known to the principal executive officer and the principal financial officer. The Company and each of its
Subsidiaries have utilized such controls and procedures in preparing and evaluating the disclosures in the Registration Statement, in the Time of Sale Disclosure Package and in the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxvii) <U><I>Anti-Bribery and Anti-Money Laundering Laws</I></U>. The Company and each of its Subsidiaries, any of their
respective officers and directors and, to the knowledge of the Company, any of their respective affiliates, agents and employees have not violated, its participation in the offering contemplated hereby will not violate, and the Company and each of
its Subsidiaries has instituted and maintains policies and procedures designed to ensure continued compliance with, each of the following laws: anti-bribery laws, including but not limited to, any applicable law, rule, or regulation of any locality,
including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, signed December&nbsp;17, 1997, including the U.S. Foreign
Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule or regulation of similar purposes and scope or anti-money laundering laws, including but not limited to, applicable federal, state, international, foreign
or other laws, regulations or government guidance regarding anti-money laundering, including, without limitation, Title 18 US. Code section 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and international anti-money laundering principles or
procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money Laundering, of which the United States is a member and with which designation the United States representative to the group or organization
continues to concur, all as amended, and any Executive order, directive, or regulation pursuant to the authority of any of the foregoing, or any orders or licenses issued thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxviii) <U><I>OFAC</I></U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) Neither the Company nor any of its Subsidiaries nor any of their respective officers or directors nor, to the knowledge of
the Company, any of their respective affiliates, employees or agents is an individual or entity that is, or is owned or controlled by an individual or entity that is: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) the subject of any sanctions administered or enforced by the U.S. Department of Treasury&#146;s Office of Foreign Assets
Control, the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury, the Swiss Secretariat of Economic Affairs, or other relevant sanctions authority (collectively, &#147;<B><I>Sanctions</I></B>&#148;), nor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) located, organized or resident in a country or territory that is the
subject of Sanctions (including, without limitation, the so-called Donetsk People&#146;s Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic, the Crimea Region of Ukraine, the
<FONT STYLE="white-space:nowrap">non-government</FONT> controlled areas of the Zaporizhzhia and Kherson Regions, Cuba, Iran, North Korea, and Syria). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) Neither the Company nor any of its Subsidiaries will, directly or indirectly, use the proceeds of the offering, or lend,
contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or other individual or entity: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) to fund or facilitate any activities or business of or with any individual or entity or in any country or territory that,
at the time of such funding or facilitation, is the subject of Sanctions; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) in any other manner that will result in
a violation of Sanctions by any individual or entity (including any individual or entity participating in the offering, whether as underwriter, advisor, investor or otherwise). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) For the past ten years, neither the Company nor any of its Subsidiaries have knowingly engaged in, and is not now
knowingly engaged in, any dealings or transactions with any individual or entity, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxix) <U><I>Compliance with Environmental Laws</I></U>. Except as disclosed in the Time of Sale Disclosure Package and the
Prospectus, neither the Company nor any of its Subsidiaries is in violation of any statute, rule, regulation, decision or order of any Governmental Authority or any court, domestic or foreign, relating to the use, disposal or release of hazardous or
toxic substances or relating to the protection or restoration of the environment or human exposure to hazardous or toxic substances (collectively, &#147;<B><I>Environmental Laws</I></B>&#148;), does not own or operate any real property contaminated
with any substance that is subject to any Environmental Laws, is liable for any <FONT STYLE="white-space:nowrap">off-site</FONT> disposal or contamination pursuant to any Environmental Laws, and is not subject to any claim relating to any
Environmental Laws, which violation, contamination, liability or claim would individually or in the aggregate, have a Material Adverse Effect; and the Company is not aware of any pending investigation which might lead to such a claim. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxx) <U><I>Compliance with Occupational Laws</I></U>. The Company and each of its Subsidiaries (A)&nbsp;is in compliance with
any and all applicable foreign, federal, state and local laws, rules, regulations, treaties, statutes and codes promulgated by any and all Governmental Authorities (including pursuant to the Occupational Health and Safety Act) relating to the
protection of human health and safety in the workplace (&#147;<B><I>Occupational Laws</I></B>&#148;); (B) has received all Permits or other approvals required of it under applicable Occupational Laws to conduct its business as currently conducted;
and (C)&nbsp;is in compliance with all terms and conditions of such Permit or approval, except in the case of each of clauses (A), (B) and (C), where such failure to be in compliance or receive approvals would reasonably be expected to result in
material liability for the Company. No action, proceeding, revocation proceeding, writ, injunction or claim is pending or, to the Company&#146;s knowledge, threatened against the Company relating to Occupational Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 14 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxi) <U><I>ERISA and Employee Benefits Matters</I></U>. (A)&nbsp;To the
knowledge of the Company, no &#147;prohibited transaction&#148; as defined under Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code and not exempt under ERISA Section&nbsp;408 and the regulations and published interpretations thereunder has
occurred with respect to any Employee Benefit Plan. At no time in the past six years has the Company, or any of its ERISA Affiliates maintained, sponsored, participated in, contributed to or incurred, or reasonably expects to incur, any liability or
obligation in respect of any Employee Benefit Plan subject to Part 3 of Subtitle B of Title I of ERISA, Title IV of ERISA, or Section&nbsp;412 of the Code or any &#147;multiemployer plan&#148; as defined in Section&nbsp;3(37) of ERISA or any
multiple employer plan for which the Company or any of its respective ERISA Affiliates has incurred or would reasonably be expected to incur liability under Section&nbsp;4063 or 4064 of ERISA. No Employee Benefit Plan provides or promises, or at any
time provided or promised, retiree health, life insurance, or other retiree welfare benefits except as may be required by the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, or similar state law. Each Employee Benefit Plan is and
has been operated in material compliance with its terms and all applicable laws, including but not limited to ERISA and the Code and, to the knowledge of the Company, no event has occurred or is reasonably expected to occur (including a
&#147;reportable event&#148; as such term is defined in Section&nbsp;4043(c) of ERISA) and no condition exists that would subject the Company, or any of its ERISA Affiliates to any material tax, fine, lien, penalty or liability imposed by ERISA, the
Code or other applicable law. Each Employee Benefit Plan intended to be qualified under Code Section&nbsp;401(a) is so qualified and has a favorable determination or opinion letter from the Internal Revenue Service upon which it can rely, and any
such determination or opinion letter remains in effect and has not been revoked; to the knowledge of the Company, nothing has occurred since the date of any such determination or opinion letter that is reasonably likely to adversely affect such
qualification; (B)&nbsp;to the knowledge of the Company, there is no pending material audit or investigation by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty Corporation or any other governmental agency or
any foreign regulatory agency with respect to any Employee Benefit Plan; (C)&nbsp;the Company has no obligations under any collective bargaining agreement with any union and, to the knowledge of the Company, no organization efforts are underway with
respect to its employees; and (D)&nbsp;the Company is not an entity deemed to hold &#147;plan assets&#148; of any such plan or account under Section&nbsp;3(42) of ERISA, <FONT STYLE="white-space:nowrap">Section&nbsp;2510.3-101</FONT> of Title 29 of
the Code of Federal Regulations, or otherwise. As used in this Agreement, &#147;<B><I>Employee Benefit Plan</I></B>&#148; means any &#147;employee benefit plan&#148; within the meaning of Section&nbsp;3(3) of ERISA, and all stock purchase, stock
option, stock-based severance, employment, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control,</FONT></FONT> medical, disability, fringe benefit, bonus, incentive, deferred compensation, employee loan and all other
employee benefit plans, agreements, programs, policies or other arrangements, whether or not subject to ERISA, under which (x)&nbsp;any current or former employee, director or independent contractor of the Company or any of its Subsidiaries has any
present or future right to benefits or payments and which are contributed to, sponsored by or maintained by the Company or any of its respective Subsidiaries or (y)&nbsp;the Company or any of its Subsidiaries has had or has any present or future
obligation or liability; &#147;<B><I>ERISA</I></B>&#148; means the Employee Retirement Income Security Act of 1974, as amended; &#147;<B><I>ERISA Affiliate</I></B>&#148; means any member of a company&#146;s controlled group as defined in Code
Section&nbsp;414(b), (c), (m) or (o). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 15 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxii) <U><I>Business Arrangements</I></U>. Except as disclosed in the
Registration Statement, the Time of Sale Disclosure Package and the Prospectus, neither the Company nor any of its Subsidiaries have granted rights to develop, manufacture, produce, assemble, distribute, license, market or sell its products to any
other person and is not bound by any agreement that affects the exclusive right of the Company or such Subsidiary to develop, manufacture, produce, assemble, distribute, license, market or sell its products. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxiii) <U><I>Labor Matters</I></U>. No labor dispute with the employees of the Company or any of its Subsidiaries exists or,
to the knowledge of the Company, has been threatened, and the Company is not aware of any existing or, to the knowledge of the Company, threatened, labor disturbance by the employees of any of its Subsidiaries, principal suppliers, contractors or
customers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxiv) <U><I>Disclosure of Legal Matters</I></U>. There are no statutes, regulations, legal or governmental
proceedings or contracts or other documents required to be described in the Time of Sale Disclosure Package or in the Prospectus or included as exhibits to the Registration Statement that are not described or included as required. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxv) <U><I>Statistical Information</I></U>. Any third-party statistical and market-related data included in the Registration
Statement, the Time of Sale Disclosure Package and the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate in all material respects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxvi) <U><I>Forward-looking Statements</I></U>. No forward-looking statement (within the meaning of Section&nbsp;27A of the
Act and Section&nbsp;21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxvii) <U><I>Regulatory Compliance</I></U>. Except as described in the Registration Statement, the Time of Sale Disclosure
Package and the Prospectus, the Company and each of its Subsidiaries: (A)&nbsp;has not received any Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or written notice from the FDA or any other Governmental
Authority alleging or asserting material noncompliance with the terms of any Permits; (B)&nbsp;the Company and each of its Subsidiaries is not in violation in any material respect of any term of any Permit; (C)&nbsp;has not received notice that any
Governmental Authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Permit and has no knowledge that any such Governmental Authority is considering such action; (D)&nbsp;(1) has filed, obtained,
maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws or Permit (&#147;<B><I>Submissions</I></B>&#148;), and (2)&nbsp;all
such Submissions were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); (E) has not, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 16 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any material recall, market withdrawal or replacement, safety alert, post-sale
warning, &#147;dear doctor&#148; letter, or other notice of action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation; and (F)&nbsp;has not, and to the knowledge of the Company, the
Company&#146;s and each of its Subsidiaries&#146; respective officers, employees and agents have not, made any untrue statement of a material fact or fraudulent statement to any Governmental Authority or failed to disclose a material fact required
to be disclosed to any Governmental Authority. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxviii) <U><I>Studies, Tests and Trials</I></U>. The clinical trials and
other studies (collectively, &#147;<B><I>Studies</I></B>&#148;) conducted by or on behalf of or sponsored by the Company and each of its Subsidiaries or in which the Company, its Subsidiaries or their products have participated were and, if still
pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such Studies and all applicable laws and regulations, including, without limitation, 21 C.F.R. Parts 50, 54,
56, 58 and 812; each description of the results of such Studies included in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus is accurate and complete in all material respects and fairly presents the data derived
from such Studies, and the Company, after due inquiry, has no knowledge of any other Studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Time of
Sale Disclosure Package or the Prospectus in any material respect, except as described therein; no investigational device exemption application filed by or on behalf of the Company or any of its Subsidiaries with the U.S. Food and Drug
Administration (&#147;<B><I>FDA</I></B>&#148;) has been terminated or suspended by the FDA, and neither the FDA nor any applicable foreign regulatory agency has commenced, or, to the knowledge of the Company, threatened to initiate, any action to
place a clinical hold order on, or otherwise terminate, delay or suspend, any proposed or ongoing Studies conducted or proposed to be conducted by or on behalf of the Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxix) <U><I>Compliance with Health Care Laws</I></U>. The Company and each of its Subsidiaries have operated and has been in
material compliance with all applicable health care laws, rules and regulations, including, (i)&nbsp;the Federal Food Drug and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.); (ii) applicable federal, state, local and applicable foreign healthcare
related fraud and abuse laws, including, the federal Anti-kickback Statute (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(b)),</FONT> the civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the criminal False Claims Law (42
U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(a)),</FONT> criminal laws relating to health care fraud and abuse, including 18 U.S.C. &#167;&#167; 286 and 287, the health care fraud criminal provisions under the U.S. Health Insurance
Portability and Accountability Act of 1996 (&#147;<B><I>HIPAA</I></B>&#148;) (42 U.S.C. &#167;&#167; 1320d et seq.), the exclusion law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> and the civil monetary penalties law (42
U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a)</FONT> and the U.S. Physician Payments Sunshine Act (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7h);</FONT> (iii) Medicare (Title XVIII of the Social Security Act); (iv) Medicaid
(Title XIX of the Social Security Act); (v) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. &#167;&#167; 17921 et seq.); (vi) the regulations promulgated pursuant to such laws; and
(viii)&nbsp;other similar local, state, federal, or foreign laws (collectively, the &#147;<B><I>Health Care Laws</I></B>&#148;); neither the Company nor any of its Subsidiaries nor any of their respective officers, directors, or to the
Company&#146;s knowledge, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 17 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
its employees or agents, have engaged in activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or
any other state or federal healthcare program (collectively, the &#147;<B><I>Programs</I></B>&#148;); neither the Company nor any of its Subsidiaries have received notice or other correspondence of any material claim, action, suit, audit, survey,
proceeding, hearing, enforcement, investigation, arbitration or other action (&#147;<B><I>Action</I></B>&#148;) from any Government Authority or third party alleging that any product operation or activity is in material violation of any Health Care
Laws, and, to the Company&#146;s knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened; neither the Company nor any of its Subsidiaries are a party to, and have any ongoing
reporting obligations pursuant to any corporate integrity agreement, deferred prosecution agreement, monitoring agreement, consent decree, settlement order, plan of correction or similar agreement imposed by any Government Authority; additionally,
neither the Company nor any of its Subsidiaries nor any of their respective officers or directors nor, to the Company&#146;s knowledge, any of its employees or agents have been excluded, suspended or debarred from participation in the Programs or
human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion from the
Programs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xl) <U><I>Cybersecurity</I></U>. The Company&#146;s and each of its Subsidiaries&#146; information technology
assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<B><I>IT Systems</I></B>&#148;) are adequate for, and operate and perform in all material respects as required in
connection with the operation of the business of the Company and each of its Subsidiaries as currently conducted, to the knowledge of the Company, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other
corruptants. The Company and each of its Subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential
information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including &#147;Personal Data,&#148; used in connection with their businesses. &#147;<B><I>Personal Data</I></B>&#148; means (i)&nbsp;a natural
person&#146;s name, street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s license number, passport number, credit card number, bank
information, or customer or account number; (ii)&nbsp;any information which would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended; (iii) &#147;personal data&#148; as defined by GDPR (as
defined below); (iv) any information which would qualify as &#147;protected health information&#148; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical
Health Act (collectively, &#147;<B><I>HIPAA</I></B>&#148;); and (v)&nbsp;any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an
identified person&#146;s health or sexual orientation. To the knowledge of the Company, there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or
liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and each of its Subsidiaries are presently in material compliance with all
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 18 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations
relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xli) <U><I>Compliance with Data Privacy Laws</I></U>. The Company and each of its Subsidiaries are, and since
December&nbsp;31, 2021 have been, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and each of its Subsidiaries have taken commercially
reasonable actions to prepare to comply with, and since December&nbsp;31, 2021, has been and currently is in compliance with, the European Union General Data Protection Regulation (&#147;<B><I>GDPR</I></B>&#148;) (EU 2016/679) (collectively, the
&#147;<B><I>Privacy Laws</I></B>&#148;). To ensure compliance with the Privacy Laws, the Company and each of its Subsidiaries have in place, complies with, and takes appropriate steps reasonably designed to ensure compliance in all material respects
with its policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the &#147;<B><I>Policies</I></B>&#148;). Since December&nbsp;31, 2021, the Company and each
of its Subsidiaries have made all disclosures to users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate
or in violation of any applicable laws and regulatory rules or requirements in any material respect. The Company further certifies that neither it nor any of its Subsidiaries: (i)&nbsp;has received notice of any actual or potential liability under
or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;is currently conducting or paying for, in whole or
in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I><U>Effect of Certificates</U></I>. Any certificate signed by any officer of the Company and delivered to you or to counsel for the
Underwriters shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.
<B><I>Purchase, Sale and Delivery of Securities</I></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I><U>Firm Shares</U></I>. On the basis of the representations, warranties
and agreements herein contained, but subject to the terms and conditions herein set forth, the Company agrees to issue and sell the Firm Shares, to the several Underwriters, and each Underwriter agrees, severally and not jointly, to purchase from
the Company the number of Firm Shares set forth opposite the name of such Underwriter in Schedule&nbsp;I hereto. The purchase price for each Firm Share shall be $2.115 per share. The obligation of each Underwriter to the Company shall be to purchase
from the Company that number of Firm Shares (to be adjusted by the Representative to avoid fractional shares) which represents the same proportion of the number of Firm Shares to be sold by the Company pursuant to this Agreement as the number of
Firm Shares set forth opposite the name of such Underwriter in Schedule&nbsp;I hereto represents to the total number of Firm Shares to be purchased by all Underwriters pursuant to this Agreement. In making this Agreement, each Underwriter is
contracting severally and not jointly; except as provided in paragraph&nbsp;(c) of this Section&nbsp;3 and in Section&nbsp;8 hereof, the agreement of each Underwriter is to purchase only the respective number of Firm Shares specified in
Schedule&nbsp;I. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 19 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Firm Shares will be delivered by the Company to you for the accounts of the several
Underwriters against payment of the purchase price therefor by wire transfer of same day funds payable to the order of the Company, as appropriate, at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston,
MA 02111, or such other location as may be mutually acceptable, at 9:00&nbsp;a.m. Central time on the first (or if the Securities are priced, as contemplated by Rule <FONT STYLE="white-space:nowrap">15c6-1(c)</FONT> under the Exchange Act, after
4:30 p.m. Eastern time, the second) full business day following the date hereof, or at such other time and date as you and the Company determine pursuant to Rule <FONT STYLE="white-space:nowrap">15c6-1(a)</FONT> under the Exchange Act, such time and
date of delivery being herein referred to as the &#147;<B><I>First Closing Date</I></B>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I><U>Option Shares</U></I>. On the
basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions herein set forth, the Company hereby grants to the several Underwriters an option to purchase all or any portion of the Option Shares
at the same purchase price as the Firm Shares. The option granted hereunder may be exercised in whole or in part at any time (but not more than once) within 30 days after the effective date of this Agreement upon notice (confirmed in writing) by the
Representative to the Company setting forth the aggregate number of Option Shares as to which the several Underwriters are exercising the option and the date and time, as determined by you, when the Option Shares are to be delivered, such time and
date being herein referred to as the &#147;<B><I>Second Closing</I></B>&#148; and &#147;<B><I>Second Closing Date</I></B>,&#148; respectively, provided, however, that the Second Closing Date shall not be earlier than the First Closing Date nor
earlier than the first business day after the date on which the option shall have been exercised. The number of Option Shares to be purchased by each Underwriter shall be the same percentage of the total number of Option Shares to be purchased by
the several Underwriters as the number of Firm Shares to be purchased by such Underwriter is of the total number of Firm Shares to be purchased by the several Underwriters, as adjusted by the Representative in such manner as the Representative deem
advisable to avoid fractional shares. No Option Shares shall be sold and delivered unless the Firm Shares previously have been, or simultaneously are, sold and delivered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Option Shares will be delivered by the Company, as appropriate, to you for the accounts of the several Underwriters against payment of the
purchase price therefor by wire transfer of same day funds payable to the order of the Company at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111, or such other location as may be mutually
acceptable at 9:00&nbsp;a.m., Central time, on the Second Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I><U>Delivery</U></I>. Delivery of the Firm Shares or the
Option Shares will be made by credit through full fast transfer to the accounts at the Depository Trust Company designated by the Representative. In the event that the Firm Shares (and Option Shares, if elected by the Representative) are not
delivered to the Representative by 2:30 p.m., New York City time, on the First Closing Date (and the Second Closing Date, if elected by the Representative), the Company will return payment of the full purchase price to the Representative via same
day funds by 4:30 p.m., New York City time. The Company shall remain liable to the Representative for the full amount of the purchase price and any costs associated with recovering the purchase price until the full amount has been received by the
Representative. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 20 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <I><U>Purchase by Representative on Behalf of Underwriters</U></I>. It is understood
that you, individually and not as Representative of the several Underwriters, may (but shall not be obligated to) make payment to the Company, on behalf of any Underwriter for the Securities to be purchased by such Underwriter. Any such payment by
you shall not relieve any such Underwriter of any of its obligations hereunder. Nothing herein contained shall constitute any of the Underwriters an unincorporated association or partner with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B><I>Covenants</I></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I><U>Covenants of the Company</U></I>. The Company covenants and agrees with the several Underwriters as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U><I>Required Filings</I></U>. During the period beginning on the date hereof and ending on the later of the Second
Closing Date or such date, as in the opinion of counsel for the Underwriters, the Prospectus is no longer required by law to be delivered (assuming the absence of Rule 172 under the Securities Act), in connection with sales by an Underwriter or
dealer (the &#147;<B><I>Prospectus Delivery Period</I></B>&#148;), prior to amending or supplementing the Registration Statement including any Rule 462(b) Registration Statement), the Time of Sale Disclosure Package or the Prospectus, the Company
shall furnish to the Representative for review a copy of each such proposed amendment or supplement, and the Company shall not file any such proposed amendment or supplement to which the Representative or counsel to the Underwriters reasonably
object. Subject to this Section&nbsp;4(a)(i), immediately following execution of this Agreement, the Company will prepare the Prospectus containing the Rule 430B Information and other selling terms of the Securities, the plan of distribution thereof
and such other information as may be required by the Securities Act or the Rules and Regulations or as the Representative and the Company may deem appropriate, and if requested by the Representative, an issuer free writing prospectus containing the
selling terms of the Securities and such other information as the Company and the Representative may deem appropriate, and will file or transmit for filing with the Commission, in accordance with Rule 424(b) or Rule 433, as the case may be, copies
of the Prospectus and each issuer free writing prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) <U><I>Notification of Certain Commission Actions</I></U>.
During the Propsectus Delivery Period, the Company shall promptly advise the Representative in writing (A)&nbsp;of the receipt of any comments of, or requests for additional or supplemental information from, the Commission, (B)&nbsp;of the time and
date of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to any Preliminary Prospectus, the Time of Sale Disclosure Package or the Prospectus, (C)&nbsp;of the time and date that any
post-effective amendment to the Registration Statement becomes effective, (D)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or of any order
preventing or suspending its use or the use of any Preliminary Prospectus, the Time of Sale Disclosure Package, the Prospectus or any issuer free writing prospectus, or (E)&nbsp;of any proceedings to remove, suspend or terminate from listing or
quotation the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 21 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Common Stock from any securities exchange upon which it is listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such
purposes. If the Commission shall enter any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order at the earliest possible moment. Additionally, the Company agrees that it shall comply with the
provisions of Rules 424(b), 430A and 430B, as applicable, under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b), Rule 433 or Rule 462 were received in a timely manner by the
Commission (without reliance on Rule 424(b)(8) or Rule 164(b)). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) <U><I>Continued Compliance with Securities
Laws</I></U>. (A)&nbsp;During the Prospectus Delivery Period, the Company will comply as far as it is able with all requirements imposed upon it by the Securities Act, as now and hereafter amended, and by the Rules and Regulations, as from time to
time in force, and by the Exchange Act so far as necessary to permit the continuance of sales of or dealings in the Securities as contemplated by the provisions hereof, the Time of Sale Disclosure Package and the Prospectus. If during such period
any event occurs as a result of which the Prospectus (or if the Prospectus is not yet available to prospective purchasers, the Time of Sale Disclosure Package) would include an untrue statement of a material fact or omit to state a material fact
necessary to make the statements therein, in the light of the circumstances then existing, not misleading, or if during such period it is necessary or appropriate in the opinion of the Company or its counsel or the Representative or counsel to the
Underwriters to amend the Registration Statement or supplement the Prospectus (or, if the Prospectus is not yet available to prospective purchasers, the Time of Sale Disclosure Package) to comply with the Securities Act or to file under the Exchange
Act any document which would be deemed to be incorporated by reference in the Prospectus in order to comply with the Securities Act or the Exchange Act, the Company promptly will (x)&nbsp;notify you of such untrue statement or omission,
(y)&nbsp;amend the Registration Statement or supplement the Prospectus (or, if the Prospectus is not yet available to prospective purchasers, the Time of Sale Disclosure Package) or file such document (at the expense of the Company) so as to correct
such statement or omission or effect such compliance, and (z)&nbsp;notify you when any amendment to the Registration Statement is filed or becomes effective or when any supplement to the Prospectus (or, if the Prospectus is not yet available to
prospective purchasers, the Time of Sale Disclosure Package) is filed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) If at any time following issuance of an issuer
free writing prospectus there occurred or occurs an event or development as a result of which such issuer free writing prospectus conflicted or would conflict with the information contained in the Registration Statement, the Preliminary Prospectus
or the Prospectus or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at that
subsequent time, not misleading, the Company (x)&nbsp;has promptly notified or promptly will notify the Representative of such conflict, untrue statement or omission, (y)&nbsp;has promptly amended or will promptly amend or supplement, at its own
expense, such issuer free writing prospectus to eliminate or correct such conflict, untrue statement or omission, and (2)&nbsp;has notified or promptly will notify you when such amendment or supplement was or is filed with the Commission where so
required to be filed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 22 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) If immediately prior to the third anniversary of the initial effective
date of the Registration Statement, any of the Securities remain unsold by the Underwriters, the Company will prior to that third anniversary file, if it has not already done so, a new shelf registration statement relating to the Securities, in a
form satisfactory to the Representative, will use its best efforts to cause such registration statement to be declared effective within 180 days after that third anniversary, and will take all other action necessary or appropriate to permit the
public offering and sale of the Securities to continue as contemplated in the expired registration statement relating to the Securities. References herein to the Registration Statement shall include such new shelf registration statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) <U><I>Blue Sky Qualifications</I></U>. The Company shall take or cause to be taken all necessary action to qualify the
Securities for sale under the securities laws of such jurisdictions as you reasonably designate and to continue such qualifications in effect so long as required for the distribution of the Securities, except that the Company shall not be required
in connection therewith to qualify as a foreign corporation (where not otherwise required), subject itself to taxation in any jurisdiction where not otherwise required, or to execute a general consent to service of process in any jurisdiction (where
not otherwise required). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) <U><I>Provision of Documents</I></U>. The Company will furnish, at its own expense, to the
Underwriters and counsel for the Underwriters copies of the Registration Statement (three of which will be signed and will include all consents and exhibits filed therewith), and to the Underwriters and any dealer each Preliminary Prospectus, the
Time of Sale Disclosure Package, the Prospectus, any issuer free writing prospectus, and all amendments and supplements to such documents, in each case as soon as available and in such quantities as you may from time to time reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) <U><I>Rule 158</I></U>. The Company will make generally available to its security holders as soon as practicable, but in
no event later than 15 months after the end of the Company&#146;s current fiscal quarter, an earnings statement (which need not be audited) covering a <FONT STYLE="white-space:nowrap">12-month</FONT> period that shall satisfy the provisions of
Section&nbsp;11(a) of the Securities Act and Rule&nbsp;158 of the Rules and Regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) <U><I>Payment and
Reimbursement of Expenses</I></U>. The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, will pay or cause to be paid (A)&nbsp;all expenses (including transfer taxes allocated to the
respective transferees) incurred in connection with the delivery to the Underwriters of the Securities, (B)&nbsp;all expenses and fees (including, without limitation, fees and expenses of the Company&#146;s accountants and counsel but, except as
otherwise provided below, not including fees of the Underwriters&#146; counsel) in connection with the preparation, printing, filing, delivery, and shipping of the Registration Statement (including the financial statements therein and all
amendments, schedules, and exhibits thereto), the Securities, each Preliminary Prospectus, the Time of Sale Disclosure Package, the Prospectus, any issuer free writing prospectus and any amendment thereof or supplement thereto, and the printing,
delivery, and shipping of this Agreement and other underwriting documents, including Blue Sky Memoranda (covering the states and other applicable jurisdictions), (C) all filing fees and fees and the reasonable disbursements of the Underwriters&#146;
counsel </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 23 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
incurred in connection with the qualification of the Securities for offering and sale by the Underwriters or by dealers under the securities or blue sky laws of the states and other jurisdictions
which you shall designate, (D)&nbsp;the fees and expenses of any transfer agent or registrar, (E)&nbsp;the filing fees and fees and disbursements of Underwriters&#146; counsel incident to any required review and approval by FINRA of the terms of the
sale of the Securities, (F)&nbsp;listing fees, if any, (G)&nbsp;the cost and expenses of the Company relating to investor presentations or any &#147;road show&#148; undertaken in connection with marketing of the Securities, including, without
limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road
show presentations with the prior approval of the Company, travel and lodging expenses of the representatives and officers of the Company and, with the prior approval of the Company, any such consultants, and 50% of the cost of any aircraft
chartered in connection with the road show (the remaining 50% to be paid for by the Underwriters), (H) the reasonable fees and disbursements of counsel to the Underwriters in connection with the transactions contemplated in this Agreement, and
(I)&nbsp;all other costs and expenses of the Company incident to the performance of its obligations hereunder that are not otherwise specifically provided for herein; provided, however, that such costs and expenses provided for in clauses (C), (E)
and (H)&nbsp;shall not exceed $100,000 in the aggregate (or, in the event the transactions contemplated hereunder are not consummated or this Agreement is terminated, $50,000 in the aggregate). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) <U><I>Use of Proceeds</I></U>. The Company will apply the net proceeds from the sale of the Securities to be sold by it
hereunder for the purposes set forth in the Time of Sale Disclosure Package and in the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) <U><I>Company Lock
Up</I></U>. The Company will not, without the prior written consent of the Representative, from the date of execution of this Agreement and continuing to and including the date 90 days after the date of the Prospectus (the &#147;<B><I><FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#148;), (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or
warrant to purchase or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or (ii)&nbsp;enter into any swap or other agreement that
transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (i)&nbsp;or (ii)&nbsp;above is to be settled by delivery of Common Stock or such other securities, in
cash or otherwise, except (A)&nbsp;to the Underwriters pursuant to this Agreement, (B)&nbsp;the issuance by the Company of shares of Common Stock upon the exercise of any stock options or warrants, or upon the conversion of any shares of preferred
stock of the Company, outstanding as of the date hereof and disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus; (C)&nbsp;the issuance by the Company of shares of Common Stock or securities convertible
into shares of Common Stock pursuant to the Company&#146;s equity incentive plans in effect on the date hereof and described in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus; (D)&nbsp;the filing of a registration
statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> with respect to the Company&#146;s equity incentive plans in effect on the date hereof and described in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus;
or (E)&nbsp;the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 24 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
sale or issuance of or entry into an agreement providing for the issuance of shares of Common Stock, or any security convertible into or exercisable for shares of Common Stock, in connection with
the acquisition by the Company of the securities, business or assets of another person or entity or pursuant to an employee benefit plan assumed by the Company in connection with such acquisition, or in connection with joint ventures, commercial
relationships or other strategic transactions; provided, that the aggregate number of shares of Common Stock that the Company may sell or issue or agree to sell or issue pursuant to this clause (E)&nbsp;shall not exceed 5% of the total number of
shares of Common Stock issued and outstanding immediately following the completion of the transactions contemplated by this Agreement, and provided further, that the Company shall cause each recipient of such shares or other securities to execute
and deliver to you, on or prior to such issuance, a <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and issue stop order restrictions to its transfer agent and registrar for the Common Stock with respect to any transaction or contemplated
transaction that would constitute a breach of or default under the applicable <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) <U><I>Stockholder <FONT STYLE="white-space:nowrap">Lock-Ups</FONT></I></U>. The Company has caused to be delivered to you
prior to the date of this Agreement a letter, in the form of Exhibit A hereto (the &#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</I></B>&#148;), from each director, executive officer, and securityholder listed on Schedule IV.
The Company will enforce the terms of each <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and issue stop-transfer instructions to the transfer agent for the Common Stock with respect to any transaction or contemplated transaction that
would constitute a breach of or default under the applicable <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi) <U><I>No Market Stabilization or Manipulation</I></U>. The Company has not taken and will not take, directly or
indirectly, any action designed to or which might reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the
Securities </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xii) <U><I>SEC Reports</I></U>. During the Prospectus Delivery Period, the Company will file on a timely basis
with the Commission such periodic and special reports as required by the Rules and Regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiii)
<U><I>Sarbanes-Oxley</I></U>. To the extent legally required, the Company and each of its Subsidiaries will comply with all provisions of the Sarbanes-Oxley Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiv) <U><I>Free Writing Prospectuses</I></U>. The Company represents and agrees that, unless it obtains the prior written
consent of the Representative, and each Underwriter severally represents and agrees that, unless it obtains the prior written consent of the Company and the Representative, it has not made and will not make any offer relating to the Securities that
would constitute an issuer free writing prospectus or that would otherwise constitute a free writing prospectus required to be filed with the Commission; provided that the prior written consent of the parties hereto shall be deemed to have been
given in respect of the free writing prospectuses included in Schedule&nbsp;II. Any such free writing prospectus consented to by the Company and the Representative is hereinafter referred to as a &#147;<B><I>Permitted Free Writing
Prospectus</I></B>.&#148; The Company represents that it has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 25 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
treated or agrees that it will treat each Permitted Free Writing Prospectus as an issuer free writing prospectus, and has complied and will comply with the requirements of Rules&nbsp;164 and 433
of the Rules and Regulations applicable to any Permitted Free Writing Prospectus. The Company agrees not to take any action that would result in the Company being required to file with the Commission under Rule&nbsp;433(d) a free writing prospectus
prepared by or on behalf of the Company that otherwise would not be required to be filed by the Company thereunder, but for the action of the Company. Each Underwriter severally represents and agrees that, (A)&nbsp;unless it obtains the prior
written consent of the Company and the Representative, it has not distributed, and will not distribute any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication other than those
listed on Schedule&nbsp;V, and (B)&nbsp;any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication undertaken by it was with entities that are qualified institutional buyers with the meaning
of Rule&nbsp;144A under the Act or institutions that are accredited investors within the meaning of Rule&nbsp;501 under the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.
<B><I>Conditions of Underwriters&#146; Obligations</I></B>. The obligations of the several Underwriters hereunder are subject to the accuracy, as of the date hereof and at each of the First Closing Date and the Second Closing Date (each, a
&#147;<B><I>Closing Date</I></B>&#148;) (as if made at such Closing Date), of and compliance with all representations, warranties and agreements of the Company contained herein, to the performance by the Company of its respective obligations
hereunder and to the following additional conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I><U>Required Filings; Absence of Certain Commission Actions</U></I>. If filing
of the Prospectus, or any amendment or supplement thereto, or any issuer free writing prospectus, is required under the Securities Act or the Rules and Regulations, the Company shall have filed the Prospectus (or such amendment or supplement) or
such issuer free writing prospectus with the Commission in the manner and within the time period so required (without reliance on Rule&nbsp;424(b)(8) or Rule 164(b)); the Registration Statement shall remain effective; no stop order suspending the
effectiveness of the Registration Statement or any part thereof, any Rule 462(b) Registration Statement, or any amendment thereof, nor suspending or preventing the use of the Time of Sale Disclosure Package, the Prospectus or any issuer free writing
prospectus shall have been issued; no proceedings for the issuance of such an order shall have been initiated or threatened; any request of the Commission for additional information (to be included in the Registration Statement, the Time of Sale
Disclosure Package, the Prospectus, any issuer free writing prospectus or otherwise) shall have been complied with to your satisfaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I><U>Continued Compliance with Securities Laws</U></I>. No Underwriter shall have advised the Company that (i)&nbsp;the Registration
Statement or any amendment thereof or supplement thereto contains an untrue statement of a material fact which, in your opinion, is material or omits to state a material fact which, in your opinion, is required to be stated therein or necessary to
make the statements therein not misleading, or (ii)&nbsp;the Time of Sale Disclosure Package or the Prospectus, or any amendment thereof or supplement thereto, or any issuer free writing prospectus contains an untrue statement of fact which, in your
opinion, is material, or omits to state a fact which, in your opinion, is material and is required to be stated therein, or necessary to make the statements therein, in light of the circumstances under which they are made, not misleading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 26 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I><U>Absence of Certain Events</U></I>. Except as contemplated in the Time of Sale
Disclosure Package and in the Prospectus, subsequent to the respective dates as of which information is given in the Time of Sale Disclosure Package, neither the Company nor any of its Subsidiaries shall have incurred any material liabilities or
obligations, direct or contingent, or entered into any material transactions, or declared or paid any dividends or made any distribution of any kind with respect to its capital stock; and there shall not have been any change in the capital stock
(other than a change in the number of outstanding shares of Common Stock due to the issuance of shares upon the exercise of outstanding options or warrants or conversion of convertible securities), or any material change in the short-term or
long-term debt of the Company (other than as a result of the conversion of convertible securities), or any issuance of options, warrants, convertible securities or other rights to purchase the capital stock of the Company or any of its Subsidiaries,
or any Material Adverse Effect or any development involving a prospective Material Adverse Effect (whether or not arising in the ordinary course of business), or any loss by strike, fire, flood, earthquake, accident or other calamity, whether or not
covered by insurance, incurred by the Company or any Subsidiary, the effect of which, in any such case described above, in your judgment, makes it impractical or inadvisable to offer or deliver the Securities on the terms and in the manner
contemplated in the Time of Sale Disclosure Package and in the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <I><U>No Downgrade</U></I>. On or after the Time of Sale
(i)&nbsp;no downgrading shall have occurred in the rating accorded any of the Company&#146;s securities by any &#147;nationally recognized statistical organization,&#148; as that term is defined by the Commission for purposes of Rule&nbsp;436(g)(2)
under the Securities Act, and (ii)&nbsp;no such organization shall have publicly announced that it has under surveillance or review, with possible negative implications, its rating of any of the Company&#146;s securities or; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <I><U>Opinion of Company Counsel</U></I>. On each Closing Date, there shall have been furnished to you, as Representative of the several
Underwriters, the opinion and negative assurance letter of Ballard Spahr LLP, counsel for the Company, dated such Closing Date and addressed to you and in such form and substance as is reasonably satisfactory to the Representative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <I><U>Opinion of Intellectual Property Counsel</U></I>. On each Closing Date, there shall have been furnished to you, as Representative of
the several Underwriters, the opinion of Flaster Greenberg PC, intellectual property counsel for the Company, dated such Closing Date and addressed to you in such form and substance as is reasonably satisfactory to the Representative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <I><U>Opinion of Underwriters&#146; Counsel</U></I>. On each Closing Date, there shall have been furnished to you, as Representative of
the several Underwriters, the opinion and negative assurance letter from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel for the several Underwriters, dated such Closing Date and addressed to you, with respect to the formation of the
Company, the validity of the Securities, the Registration Statement, the Time of Sale Disclosure Package, the Prospectus and other related matters as you reasonably may request, and such counsel shall have received such papers and information as
they request to enable them to pass upon such matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <I><U>Comfort Letters</U></I>. On the date hereof, on the effective date of
any post-effective amendment to the Registration Statement filed after the date hereof and on each Closing Date you, as Representative of the several Underwriters, shall have received accountant&#146;s &#147;comfort&#148; letters of KPMG LLP, dated
such date and addressed to you, in form and substance satisfactory to you. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 27 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <I><U>Officers&#146; Certificate</U></I>. On each Closing Date, there shall have been
furnished to you, as Representative of the Underwriters, a certificate, dated such Closing Date and addressed to you, signed by the chief executive officer and by the chief financial officer of the Company, to the effect that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The representations and warranties of the Company in this Agreement are true and correct as if made at and as of such
Closing Date, and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to such Closing Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) No stop order or other order suspending the effectiveness of the Registration Statement or any part thereof or any
amendment thereof or the qualification of the Securities for offering or sale nor suspending or preventing the use of the Time of Sale Disclosure Package, the Prospectus or any issuer free writing prospectus, has been issued, and no proceeding for
that purpose has been instituted or, to the best of their knowledge, is contemplated by the Commission or any state or regulatory body; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Affirms the accuracy of the matters set forth in subsection (c)&nbsp;of this Section&nbsp;5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <I><U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</U></I>. The Underwriters shall have received all of the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreements referenced in Section&nbsp;4 and the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements shall remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) <I><U>FINRA No Objections</U></I>. FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and
arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) <I><U>Other Documents</U></I>. The Company shall have furnished to you and counsel for the Underwriters such additional
documents, certificates and evidence as you or they may have reasonably requested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) <I><U>Exchange Listing</U></I>. The Securities to
be delivered on such Closing Date have been approved for listing on the Nasdaq Global Market, subject to official notice of issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n)
<I><U>CFO Certificate</U></I>. On the date of this Agreement and on each Closing Date, as the case may be, the Company shall have furnished to the Representative a certificate, dated the respective dates of delivery thereof and addressed to the
Underwriters, of its chief financial officer with respect to certain financial data contained in the Time of Sale Disclosure Package and the Prospectus, providing &#147;management comfort&#148; with respect to such information, in form and substance
reasonably satisfactory to the Representative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">All such opinions, certificates, letters and other documents will be in compliance with
the provisions hereof only if they are reasonably satisfactory in form and substance to you and counsel for the Underwriters. The Company will furnish you with such conformed copies of such opinions, certificates, letters and other documents as you
shall reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 28 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B><I>Indemnification and Contribution</I></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I><U>Indemnification by the Company</U></I>. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates,
directors and officers and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Act or Section&nbsp;20 of the Exchange Act, from and against any losses, claims, damages or liabilities, joint or several, to
which such Underwriter may become subject, under the Act or otherwise (including in settlement of any litigation if such settlement is effected with the written consent of the Company), insofar as such losses, claims, damages or liabilities (or
actions in respect thereof) arise out of or are based upon: (i)&nbsp;an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, including the 430A Information and any other information deemed to be a
part of the Registration Statement at the time of effectiveness and at any subsequent time pursuant to the Rules and Regulations, if applicable, any Preliminary Prospectus, the Time of Sale Disclosure Package, the Prospectus, or any amendment or
supplement thereto, any issuer free writing prospectus, any issuer information that the Company has filed or is required to file pursuant to Rule 433(d) of the Rules and Regulations, any roadshow materials, or any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or (ii)&nbsp;the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and
will reimburse each Underwriter for any legal or other expenses reasonably incurred by it in connection with investigating or defending against such loss, claim, damage, liability or action as such expenses are incurred; <I>provided</I>,
<I>however</I>, that the Company will not be liable in any such case to the extent that any such loss, claim, damage, liability or action arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission
made in reliance upon and in conformity with written information furnished to the Company by you, or by any Underwriter through you, specifically for use in the preparation thereof; it being understood and agreed that the only information furnished
by an Underwriter consists of the information described as such in Section&nbsp;6(f). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I><U>Indemnification by the
Underwriters</U></I>. Each Underwriter will, severally and not jointly, indemnify and hold harmless the Company, its affiliates, directors and officers and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the
Act and Section&nbsp;20 of the Exchange Act, from and against any losses, claims, damages or liabilities to which the Company may become subject, under the Act or otherwise (including in settlement of any litigation, if such settlement is effected
with the written consent of such Underwriter), insofar as such losses, claims, damages or liabilities (or actions in respect thereof) (i)&nbsp;arise out of or are based upon an untrue statement or alleged untrue statement of a material fact
contained in the Registration Statement, any Preliminary Prospectus, the Time of Sale Disclosure Package, the Prospectus, or any amendment or supplement thereto, any issuer free writing prospectus, any issuer information that the Company has filed
or is required to file pursuant to Rule 433(d) of the Rules and Regulations, or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, or any road show, or (ii)&nbsp;arise out of
or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue
statement or alleged untrue statement or omission or alleged omission was made in reliance on or in conformity with written information furnished to the Company by you, or by such Underwriter through you, specifically for use in the preparation
thereof (it being understood and agreed that the only information furnished by an Underwriter consists of the information described as such in Section&nbsp;6(e)), and will reimburse the Company for any legal or other expenses reasonably incurred by
the Company in connection with investigating or defending against any such loss, claim, damage, liability or action as such expenses are incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 29 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I><U>Notice and Procedures</U></I>. Promptly after receipt by an indemnified party
under subsection (a)&nbsp;or (b)&nbsp;above of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in
writing of the commencement thereof; but the omission so to notify the indemnifying party shall not relieve the indemnifying party from any liability that it may have to any indemnified party except to the extent such indemnifying party has been
materially prejudiced by such failure (through the forfeiture of substantive rights or defenses). In case any such action shall be brought against any indemnified party, and it shall notify the indemnifying party of the commencement thereof, the
indemnifying party shall be entitled to participate in, and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified
party, and after notice from the indemnifying party to such indemnified party of the indemnifying party&#146;s election so to assume the defense thereof, the indemnifying party shall not be liable to such indemnified party under such subsection for
any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of investigation; <I>provided</I>, <I>however</I>, that if, in the sole judgment of the Representative, it
is advisable for the Underwriters to be represented as a group by separate counsel, the Representative shall have the right to employ a single counsel (in addition to local counsel) to represent the Representative and all Underwriters who may be
subject to liability arising from any claim in respect of which indemnity may be sought by the Underwriters under subsection&nbsp;(a) of this Section&nbsp;6, in which event the reasonable fees and expenses of such separate counsel shall be borne by
the indemnifying party or parties and reimbursed to the Underwriters as incurred. An indemnifying party shall not be obligated under any settlement agreement relating to any action under this Section&nbsp;6 to which it has not agreed in writing. In
addition, no indemnifying party shall, without the prior written consent of the indemnified party (which consent shall not be unreasonably withheld or delayed, effect any settlement of any pending or threatened proceeding unless such settlement
includes an unconditional release of such indemnified party for all liability on claims that are the subject matter of such proceeding and does not include a statement as to, or an admission of, fault, culpability or a failure to act by or on behalf
of an indemnified party. Notwithstanding the foregoing, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel pursuant to this Section&nbsp;6(c), such
indemnifying party agrees that it shall be liable for any settlement effected without its written consent if (i)&nbsp;such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request and
(ii)&nbsp;such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <I><U>Contribution; Limitations on Liability; <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedy</U></I>. If the indemnification
provided for in this Section&nbsp;6 is unavailable or insufficient to hold harmless an indemnified party under subsection&nbsp;(a) or (b)&nbsp;above, then each indemnifying party shall contribute to the amount paid or payable by such indemnified
party as a result of the losses, claims, damages or liabilities referred to in subsection&nbsp;(a) or (b)&nbsp;above, (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the
Underwriters on the other from the offering of the Securities or (ii)&nbsp;if the allocation provided by clause&nbsp;(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to in clause&nbsp;(i) above but also the relative fault of the Company on the one hand and the Underwriters on the other in connection with the statements or omissions that resulted in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 30 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the
other shall be deemed to be in the same proportion as the total net proceeds from the offering (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions received by the Underwriters, in each case as
set forth in the table on the cover page of the Prospectus. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a
material fact relates to information supplied by the Company or the Underwriters and the parties&#146; relevant intent, knowledge, access to information and opportunity to correct or prevent such untrue statement or omission. The Company and the
Underwriters agree that it would not be just and equitable if contributions pursuant to this subsection&nbsp;(d) were to be determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other
method of allocation which does not take account of the equitable considerations referred to in the first sentence of this subsection&nbsp;(d). The amount paid by an indemnified party as a result of the losses, claims, damages or liabilities
referred to in the first sentence of this subsection&nbsp;(d) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending against any action or claim which is the
subject of this subsection&nbsp;(d). Notwithstanding the provisions of this subsection&nbsp;(d), no Underwriter shall be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by
such Underwriter with respect to the Securities purchased by it hereunder exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged
omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146;
obligations in this subsection&nbsp;(d) to contribute are several in proportion to their respective underwriting obligations and not joint. The remedies provided for in this Section&nbsp;6 are not exclusive and shall not limit any rights or remedies
that might otherwise be available to any indemnified party at law or in equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <I><U>Information Provided by the
Underwriters</U></I>. The Underwriters severally confirm and the Company acknowledges that the statements with respect to the public offering of the Securities by the Underwriters set forth in the sixth, sixteenth through nineteenth, and
twenty-first paragraphs under the caption &#147;Underwriting&#148; in the Time of Sale Disclosure Package and in the Prospectus are correct and constitute the only information concerning such Underwriters furnished in writing to the Company by or on
behalf of the Underwriters specifically for inclusion in the Registration Statement, any Preliminary Prospectus, the Time of Sale Disclosure Package, the Prospectus or any issuer free writing prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <B><I>Representations and Agreements to Survive Delivery</I></B>. All representations, warranties, and agreements of the Company herein or
in certificates delivered pursuant hereto, including but not limited to the agreements of the several Underwriters, the Company contained in Section&nbsp;6 hereof, shall remain operative and in full force and effect regardless of any investigation
made by or on behalf of any Underwriter or any controlling person thereof, or the Company or any of its officers, directors, or controlling persons, and shall survive delivery of, and payment for, the Securities to and by the Underwriters hereunder
and any termination of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 31 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <B><I>Substitution of Underwriters</I></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I><U>Obligation to Purchase Under Certain Circumstances</U></I>. If any Underwriter or Underwriters shall fail to take up and pay for the
amount of Firm Shares agreed by such Underwriter or Underwriters to be purchased hereunder, upon tender of such Firm Shares in accordance with the terms hereof, and the amount of Firm Shares not purchased does not aggregate more than 10% of the
total amount of Firm Shares set forth in Schedule&nbsp;I hereto, the remaining Underwriters shall be obligated to take up and pay for (in proportion to their respective underwriting obligations hereunder as set forth in Schedule&nbsp;I hereto except
as may otherwise be determined by you) the Firm Shares that the withdrawing or defaulting Underwriters agreed but failed to purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
<I><U>Termination Under Certain Circumstances</U></I>. If any Underwriter or Underwriters shall fail to take up and pay for the amount of Firm Shares agreed by such Underwriter or Underwriters to be purchased hereunder, upon tender of such Firm
Shares in accordance with the terms hereof, and the amount of Firm Shares not purchased aggregates more than 10% of the total amount of Firm Shares set forth in Schedule&nbsp;I hereto, and arrangements satisfactory to you for the purchase of such
Firm Shares by other persons are not made within 36 hours thereafter, this Agreement shall terminate. In the event of any such termination the Company shall not be under any liability to any Underwriter (except to the extent provided in
Section&nbsp;4(a)(vii), Section&nbsp;4(b)(i), Section&nbsp;4(b)(ii) and Section&nbsp;6 hereof) nor shall any Underwriter (other than an Underwriter who shall have failed, otherwise than for some reason permitted under this Agreement, to purchase the
amount of Firm Shares agreed by such Underwriter to be purchased hereunder) be under any liability to the Company (except to the extent provided in Section&nbsp;6 hereof). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I><U>Postponement of Closing</U></I>. If Firm Shares to which a default relates are to be purchased by the
<FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters or by any other party or parties, the Representative or the Company shall have the right to postpone the First Closing Date for not more than seven business days in order that the
necessary changes in the Registration Statement, in the Time of Sale Disclosure Package, in the Prospectus or in any other documents, as well as any other arrangements, may be effected. As used herein, the term &#147;Underwriter&#148; includes any
person substituted for an Underwriter under this Section&nbsp;8. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <I><U>No Relief from Liability</U></I>. No action taken pursuant to
this Section shall relieve any defaulting Underwriter from liability, if any, in respect of such default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <B><I>Termination of this
Agreement</I></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I><U>Right to Terminate</U></I>. You, as Representative of the several Underwriters, shall have the right to
terminate this Agreement by giving notice as hereinafter specified at any time at or prior to the First Closing Date, and the option referred to in Section&nbsp;3(b), if exercised, may be cancelled at any time prior to the Second Closing Date, if
(i)&nbsp;the Company shall have failed, refused or been unable, at or prior to such Closing Date, to perform any agreement on its part to be performed hereunder, (ii)&nbsp;any other condition of the Underwriters&#146; obligations hereunder is not
fulfilled, (iii)&nbsp;trading on the Nasdaq Stock Market or New York Stock Exchange shall have been wholly suspended, (iv)&nbsp;minimum or maximum prices for trading shall have been fixed, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 32 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maximum ranges for prices for securities shall have been required, on the Nasdaq Stock Market or New York Stock Exchange, by such exchange or by order of the Commission or any other Governmental
Authority, (v)&nbsp;a banking moratorium shall have been declared by federal or state authorities, or (vi)&nbsp;there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis that, in
your judgment, is material and adverse and makes it impractical or inadvisable to proceed with the completion of the sale of and payment for the Securities. Any such termination shall be without liability of any party to any other party except that
the provisions of Section&nbsp;4(g) and Section&nbsp;6 hereof shall at all times be effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I><U>Notice of Termination</U></I>.
If you elect to terminate this Agreement as provided in this Section, the Company shall be notified promptly by you by telephone, confirmed by letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <B><I>Default by the Company</I></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I><U>Default by the Company</U></I>. If the Company shall fail at the First Closing Date to sell and deliver the number of Securities
which it is obligated to sell hereunder, then this Agreement shall terminate without any liability on the part of any Underwriter or, except as provided in Section&nbsp;4(a)(vii), Section&nbsp;4(b)(i), Section&nbsp;4(b)(ii) and Section&nbsp;6
hereof, any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I><U>No Relief from Liability</U></I>. No action taken
pursuant to this Section shall relieve the Company from liability, if any, in respect of such default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <B><I>Notices</I></B>. Except
as otherwise provided herein, all communications hereunder shall be in writing and, if to the Underwriters, shall be mailed via overnight delivery service or hand delivered via courier to the Representative at c/o Canaccord Genuity LLC, One Post
Office Square, Suite 3000, Boston, MA 02109, Attention: General Counsel, with a copy to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111, Attention: John Rudy; if to the Company, shall be mailed or
delivered to it at 3222 Phoenixville Pike, Malvern, PA 19355 Attention: Andrew Macan, with a copy (which shall not constitute notice) to Ballard Spahr LLP, 1735 Market Street, 51st Floor, Philadelphia, PA 19103-7599, Attention: Brian Short. Any
party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <B><I>Persons Entitled to Benefit of Agreement</I></B>. This Agreement shall inure to the benefit of and be binding upon the parties
hereto and their respective successors and assigns and the controlling persons, officers and directors referred to in Section&nbsp;6. Nothing in this Agreement is intended or shall be construed to give to any other person, firm or corporation any
legal or equitable remedy or claim under or in respect of this Agreement or any provision herein contained. The term &#147;successors and assigns&#148; as herein used shall not include any purchaser, as such purchaser, of any of the Securities from
any of the several Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <B><I>Absence of Fiduciary Relationship</I></B>. The Company acknowledges and agrees that:
(a)&nbsp;the Representative has been retained solely to act as underwriters in connection with the sale of the Securities and that no fiduciary, advisory or agency relationship between the Company and the Representative has been created in respect
of any of the transactions contemplated by this Agreement, irrespective of whether the Representative has advised or are advising the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 33 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on other matters; (b)&nbsp;the price and other terms of the Securities set forth in this Agreement were established by the Company following discussions and arms-length negotiations with the
Representative and the Company is capable of evaluating and understanding and understands and accepts the terms, risks and conditions of the transactions contemplated by this Agreement; (c)&nbsp;it has been advised that the Representative and its
affiliates are engaged in a broad range of transactions which may involve interests that differ from those of the Company and that the Representative has no obligation to disclose such interest and transactions to the Company by virtue of any
fiduciary, advisory or agency relationship; (d)&nbsp;it has been advised that the Representative is acting, in respect of the transactions contemplated by this Agreement, solely for the benefit of the Representative and the other Underwriters, and
not on behalf of the Company; (e)&nbsp;it, he or she waives to the fullest extent permitted by law, any claims it may have against the Representative for breach of fiduciary duty or alleged breach of fiduciary duty in respect of any of the
transactions contemplated by this Agreement and agrees that the Representative shall have no liability (whether direct or indirect) to the Company in respect of such a fiduciary duty claim on behalf of or in right of the Company, including
stockholders, employees or creditors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <B><I>Recognition of the U.S. Special Resolution Regimes</I></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the
transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any
such interest and obligation, were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that any
Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted
to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As used in this section: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>BHC Act Affiliate</I></B>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in
accordance with, 12 U.S.C. &#167; 1841(k); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Covered Entity</I></B>&#148; means any of the following: (i)&nbsp;a &#147;covered
entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii)&nbsp;a
&#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b); &#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R.
&#167;&#167; 252.81, 47.2 or 382.1, as applicable; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 34 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>U.S. Special Resolution Regime</I></B>&#148; means each of (i)&nbsp;the Federal
Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <B><I>Governing Law; Waiver of Jury Trial</I></B>. This Agreement and any transaction contemplated by this Agreement and any claim,
controversy or dispute arising under or related thereto shall be governed by and construed in accordance with the laws of the State of New York without regard to principles of conflict of laws that would results in the application of any other law
than the laws of the State of New York. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted
by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <B><I>Submission to Jurisdiction, Etc</I></B>. Each party hereby submits to the exclusive jurisdiction of the U.S. federal and New York
state courts sitting in the Borough of Manhattan, City of New York, in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. The parties hereby irrevocably and unconditionally waive any
objection to the laying of venue of any lawsuit, action or other proceeding in such courts, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such lawsuit, action or other proceeding
brought in any such court has been brought in an inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <B><I>Counterparts</I></B>. This Agreement may be executed in
one or more counterparts and, if executed in more than one counterpart, the executed counterparts shall each be deemed to be an original and all such counterparts shall together constitute one and the same instrument. Counterparts may be delivered
via facsimile or electronic mail (including, without limitation, &#147;pdf&#148;, &#147;tif&#148; or &#147;jpg&#148;) and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all
purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <B><I>General Provisions</I></B>. This Agreement constitutes the entire agreement of the parties to this Agreement and
supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may not be amended or modified unless in writing by all of the parties hereto,
and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The Section headings herein are for the convenience of the parties only and shall not affect the construction
or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 35 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please sign and return to the Company the enclosed duplicates of this Agreement whereupon
this Agreement will become a binding agreement between the Company and the several Underwriters in accordance with its terms. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>NEURONETICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Keith J. Sullivan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Keith J. Sullivan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: President &amp; CEO</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acting individually and as Representative of the several Underwriters named in the attached&nbsp;<U>Schedule I</U>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CANACCORD GENUITY LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeffrey G. Barlow</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Jeffrey G. Barlow</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: CEO, Canaccord Genuity U.S.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to
Underwriting Agreement </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE I </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Underwriter</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Firm&nbsp;Shares&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canaccord Genuity LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Underwriters may purchase up to an additional 1,200,000 Option Shares, to the extent the option described
in Section&nbsp;3(b) of the Agreement is exercised, in the proportions and in the manner described in the Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule I </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain Permitted Free Writing Prospectuses </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule II </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pricing Information </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Firm Shares offered:
8,000,000 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offered Shares offered: 9,200,000 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Public
offering price per share: $2.25 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule III </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE V </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule V </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8195;&#8195;&#8195;&#8195;, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canaccord
Genuity LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the representative of the underwriters named </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in Schedule I to the Underwriting Agreement </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">referred to below
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Canaccord Genuity LLC </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#8194;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">One Post Office Square, Suite 3000 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#8194;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Boston, MA 02109 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Sirs and Madams: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an inducement to the
underwriters (the &#147;<B><I>Underwriters</I></B>&#148;) to execute an underwriting agreement (the &#147;<B><I>Underwriting Agreement</I></B>&#148;) providing for a public offering (the &#147;<B><I>Offering</I></B>&#148;) of common stock (the
&#147;<B><I>Common Stock</I></B>&#148;) of Neuronetics, Inc. or any successor (by merger or otherwise) thereto (the &#147;<B><I>Company</I></B>&#148;), the undersigned, by executing this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement
(this &#147;<B><I>Agreement</I></B>&#148;), hereby agrees that without, in each case, the prior written consent of Canaccord Genuity LLC during the period specified in the second succeeding paragraph (the
&#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#148;), the undersigned will not: (1)&nbsp;offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option
or contract to sell, grant any option, right or warrant to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into, exercisable or exchangeable for or
that represent the right to receive Common Stock (including without limitation, Common Stock which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and
securities which may be issued upon exercise of a stock option or warrant) whether now owned or hereafter acquired (the &#147;<B><I>Undersigned&#146;s Securities</I></B>&#148;); (2) enter into any swap or other agreement that transfers, in whole or
in part, any of the economic consequences of ownership of the Undersigned&#146;s Securities, whether any such transaction described in clause (1)&nbsp;or (2)&nbsp;above is to be settled by delivery of Common Stock or such other securities, in cash
or otherwise; (3)&nbsp;make any demand for or exercise any right with respect to, the registration of any Common Stock or any security convertible into or exercisable or exchangeable for Common Stock; or (4)&nbsp;publicly disclose the intention to
do any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned agrees that the foregoing restrictions preclude the undersigned from engaging in any hedging or
other transaction which is designed to or which reasonably could be expected to lead to or result in a sale or disposition of the Undersigned&#146;s Securities even if such of the Undersigned&#146;s Securities would be disposed of by someone other
than the undersigned. Such prohibited hedging or other transactions would include without limitation any short sale or any purchase, sale or grant of any right (including without limitation any put or call option) with respect to any of the
Undersigned&#146;s Securities or with respect to any security that includes, relates to, or derives any significant part of its value from the Undersigned&#146;s Securities. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period will commence on the date of this
Agreement and will continue and include the date 90 days after the date of the final prospectus used to sell Common Stock in the Offering pursuant to the Underwriting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the undersigned may sell, transfer or dispose of the Undersigned&#146;s Securities: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as a <I>bona fide</I> gift or gifts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any corporation, partnership, limited liability company, trust or other entity that controls, or is
controlled by or is under common control with, the undersigned or the immediate family of the undersigned or is otherwise a direct or indirect affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to partners, members, beneficiaries (or the estates thereof) or other holders of equity interests of the
undersigned; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by testate succession or intestate succession to a legal representative, heir, beneficiary or a member of the
immediate family of the undersigned; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by operation of law, including pursuant to an order of a court (including a domestic order or a negotiated
divorce settlement) or regulatory agency, or to comply with any regulations related to the undersigned&#146;s ownership of the Undersigned&#146;s Securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pursuant to a bona fide third party tender offer, merger, consolidation or other similar transaction made to
all holders of Common Stock involving a Change of Control of the Company (including voting in favor of any such transaction or taking any other action in connection with such transaction), <I>provided</I> that in the event that the tender offer,
merger, consolidation or other such transaction is not completed, the Undersigned&#146;s Securities shall remain subject to the restrictions contained in this Agreement, and <I>provided</I> <I>further</I> that &#147;Change of Control&#148; shall
mean the transfer, in one transaction or in a series of related transactions, to a person or group of affiliated persons (other than an Underwriter pursuant to the Offering), of the Company&#146;s voting securities if, after such transfer, such
person or group of affiliated persons would hold more than 50% of the outstanding voting securities of the Company (or the surviving entity); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under
clauses (ii)&nbsp;through (vi) above; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pursuant to the Underwriting Agreement; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I>, that (x)&nbsp;in the case of clauses (i), (ii), (iv) and (vi), such transfer shall not involve a disposition for value, (y)&nbsp;in the case
of clauses (i)-(iv) and (vi), the transferee agrees in writing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the Underwriters to be bound by the terms of this Agreement, and (z)&nbsp;in the case of clauses&nbsp;(i)-(vi), no filing by any party under Section&nbsp;16(a) of the Securities Exchange Act
of 1934, as amended (the &#147;<B><I>Exchange Act</I></B>&#148;), shall be required or shall be made voluntarily in connection with such transfer. For purposes of this Agreement, &#147;immediate family&#148; shall mean any relationship by blood,
marriage, domestic partnership or adoption, not more remote than first cousin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the foregoing restrictions shall not apply
to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the exercise of stock options granted pursuant to the Company&#146;s equity incentive plans or warrants or any
other securities existing as of the date of the Underwriting Agreement, which securities are convertible into or exchangeable or exercisable for Common Stock; provided that (x)&nbsp;such restrictions shall apply to any of the Undersigned&#146;s
Securities issued upon such exercise, exchange or conversion and (y)&nbsp;no public announcement of the exercise, exchange or conversion and no filing with the Securities and Exchange Commission (the &#147;<B><I>SEC</I></B>&#148;) or other
regulatory authority in respect thereof or transactions thereunder or contemplated thereby, by the undersigned, the Company or any other person, shall be required, and no such announcement or filing is made voluntarily, by the undersigned, the
Company or any other person, prior to the expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, except for any filing required under Section&nbsp;16 of the Exchange Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the disposition of a number of shares of Common Stock necessary to pay or otherwise satisfy any tax withholding
obligations upon the vesting of equity awards granted pursuant to the Company&#146;s equity incentive plans, provided, however, that any filing under Section&nbsp;16 of the Exchange Act made in connection with such disposition shall clearly indicate
in the footnotes thereto that the filing relates to the circumstances described in this clause; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transfer or disposition of any shares of Common Stock purchased by the undersigned on the open market
following the Offering or, unless the undersigned is a director or officer of the Company, any shares of Common Stock the undersigned may purchase in the Offering, whether or not issuer directed; <I>provided</I> that prior to the expiration of the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period no filing by the undersigned under Section&nbsp;16(a) of the Exchange Act shall be required or shall be made voluntarily in connection with the transfer or disposition and that the undersigned shall
make no voluntary public announcement of the transfer or disposition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transfer of shares of Common Stock to the Company in connection with the termination of the
undersigned&#146;s employment with the Company; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the establishment of any contract, instruction or plan (a &#147;<B><I>Plan</I></B>&#148;) that satisfies all of
the applicable requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1(c)(1)(i)(B)</FONT> under the Exchange Act; <I>provided</I> that no sales of the Undersigned&#146;s Securities shall be made pursuant to such a Plan prior to the expiration
of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, and such a Plan may only be established if the undersigned makes no voluntary public announcement of the establishment or existence thereof prior to the expiration of the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period, except as required by applicable securities laws. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In furtherance of the foregoing, the Company and its transfer agent and registrar are hereby
authorized to decline to make any transfer of shares of Common Stock if such transfer would constitute a violation or breach of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Agreement and that, upon
request, the undersigned will execute any additional documents reasonably necessary to ensure the validity or enforcement of this Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be
binding upon the successors, assigns, heirs or personal representatives of the undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that this
Agreement shall automatically terminate and the undersigned shall be released from all obligations under this Agreement if (i)&nbsp;the Company notifies the Underwriters that it does not intend to proceed with the Offering, (ii)&nbsp;the
Underwriting Agreement does not become effective, or if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold
thereunder or (iii)&nbsp;the Offering is not completed by February&nbsp;28, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that the Underwriters are
entering into the Underwriting Agreement and proceeding with the Offering in reliance upon this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement and any claim,
controversy or dispute arising under or related to this Agreement shall be governed by, and construed in accordance with, the laws of the State of New York applicable to contracts made and to be performed within the State of New York. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">Printed Name of Holder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center" STYLE="padding-bottom:24pt ;BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:10pt">Signature</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Printed Name of Person Signing (and indicate capacity of person signing if signing as custodian, trustee,
or on behalf of an entity)</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d928209dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g928209dsp1.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g928209dsp1a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;7, 2025 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neuronetics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3222 Phoenixville Pike </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Malvern, PA 19355 </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neuronetics, Inc. &#150; Underwriting Agreement </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Neuronetics, Inc., a Delaware corporation (the &#147;Company&#148;), and are delivering this supplemental opinion letter in
connection with the prospectus supplement (the &#147;Prospectus Supplement&#148;) filed on February&nbsp;7, 2025 by the Company with the Securities and Exchange Commission (the &#147;Commission&#148;) pursuant to Rule 424 under the Securities Act of
1933, as amended (the &#147;Securities Act&#148;). The Prospectus Supplement relates to the offering by the Company of up to 9,200,000 shares (the &#147;Shares&#148;) of the Company&#146;s common stock, par value $0.01 per share (the &#147;Common
Stock&#148;), covered by the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-266617)</FONT> (as amended or supplemented, the &#147;Registration
Statement&#148;) filed on November&nbsp;9, 2022 with the Commission pursuant to the Securities Act, relating to the registration of the offer by the Company of up to $125,000,000 of any combination of securities of the types specified therein. The
Registration Statement was declared effective by the Commission on November&nbsp;14, 2022. The Shares include an option granted to the underwriters of the offering to purchase of up to 1,200,000 Shares. The Shares are being sold to the underwriters
named in, and pursuant to, an underwriting agreement among the Company and such underwriters (the &#147;Underwriting Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have reviewed
such documents and made such examination of law as we have deemed appropriate to give the opinion set forth below. In such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of
all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, conformed or photostatic copies and the authenticity of the originals of such latter documents. We have relied, without
independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the foregoing and subject to the limitations, qualifications and assumptions set forth herein, we are of the opinion that the Shares have been duly
authorized for issuance and, when delivered and paid for in accordance with the terms of the Underwriting Agreement, will be validly issued, fully paid <FONT STYLE="white-space:nowrap">and&nbsp;non-assessable</FONT> shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We express no opinion as to the laws of any jurisdiction other than the laws of the State of Delaware. Our opinion is limited to the matters stated herein and
no opinion is implied or may be inferred beyond the matters expressly stated. Our opinion is based on these laws as in effect on the date hereof, and we disclaim any obligation to advise you of facts, circumstances, events or developments which
hereafter may be brought to our attention and which may alter, affect or modify the opinion expressed herein. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the inclusion of this opinion as Exhibit&nbsp;5.1 to this Current Report on
Form&nbsp;8-K (and its incorporation by reference in the Registration Statement) and to the use of our firm&#146;s name under the caption &#147;Legal Matters&#148; in the Prospectus Supplement. In giving our consent, we do not admit that we are in
the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ballard Spahr </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d928209dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neuronetics Announces Launch of Underwritten Public Offering of Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MALVERN, PA., February&nbsp;6, 2025 &#150; Neuronetics, Inc. (NASDAQ: STIM) (the &#147;Company&#148;) today announced that it has commenced an underwritten
public offering of its common stock. In connection with the offering, the Company expects to grant the underwriter a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an additional 15% of the shares of common stock offered in
the public offering. All shares in the offering are being offered by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canaccord Genuity LLC is acting as sole bookrunner in connection with
the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A shelf registration statement relating to the common stock being sold in this offering was previously filed with the U.S. Securities and Exchange Commission
(the &#147;SEC&#148;) on November&nbsp;9, 2022, and was declared effective on November&nbsp;14, 2022. The offering will be made only by means of a prospectus supplement and the accompanying prospectus that form part of the registration statement. A
preliminary prospectus supplement relating to and describing the terms of the offering and accompanying prospectus will be filed with the SEC and will be available on the SEC&#146;s website located at http://www.sec.gov. When available, copies of
the preliminary prospectus supplement and accompanying prospectus can be obtained from Canaccord Genuity LLC, Attention: Syndication Department, One Post Office Square, Suite 3000, Boston, Massachusetts 02109, or by telephone at (617) <FONT
STYLE="white-space:nowrap">371-3900,</FONT> or by email at&nbsp;prospectus@cgf.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Neuronetics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neuronetics, Inc.
(&#147;Neuronetics&#148;) believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering
<FONT STYLE="white-space:nowrap">exceptional&nbsp;in-office&nbsp;treatments</FONT> that produce extraordinary results. NeuroStar Advanced Therapy (&#147;NeuroStar Therapy&#148;) is
<FONT STYLE="white-space:nowrap">a&nbsp;non-drug,&nbsp;noninvasive</FONT> treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the
NeuroStar Advanced Therapy System (the &#147;NeuroStar System&#148;) and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (&#147;Greenbrook&#148;) treatment centers across the United States, offering NeuroStar
Therapy for the treatment of major depressive disorder (&#147;MDD&#148;) and other mental health disorders. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NeuroStar Therapy is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms
for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also cleared by the U.S. Food
and Drug Administration, as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15 to 21 with MDD. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary
results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Safe harbor&#148; statement under the Private Securities Litigation Reform Act of 1995: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements in this press release, including the documents incorporated by reference herein, include &#147;forward-looking statements&#148; within the
meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws
and other applicable laws and &#147;forward-looking information&#148; within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute &#147;forward-looking statements&#148; within
the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as &#147;outlook,&#148; &#147;potential,&#148; &#147;believe,&#148; &#147;expect,&#148; &#147;plan,&#148;
&#147;anticipate,&#148; &#147;predict,&#148; &#147;may,&#148; &#147;will,&#148; &#147;could,&#148; &#147;would&#148; and &#147;should&#148; as well as the negative of these terms and similar expressions. These statements include those relating to
the proposed public offering of common stock. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to: market conditions and the completion of the public offering on the anticipated terms or at
all; the effect of the transaction with Greenbrook, on the Company&#146;s business relationships, operating results and business generally; the Company&#146;s ability to execute its business strategy; the Company&#146;s ability to achieve or sustain
profitable operations due to its history of losses; the Company&#146;s ability to successfully complete the announced restructuring plans; the Company&#146;s reliance on the sale and use of the NeuroStar Advanced Therapy System to generate revenues;
the scale and efficacy of the Company&#146;s salesforce; the Company&#146;s ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using the Company&#146;s products; physician and patient demand
for treatments using the Company&#146;s products; developments in competing technologies and therapies for the indications that the Company&#146;s products treat; product defects; the Company&#146;s revenue has been concentrated among a small number
of customers; the Company&#146;s ability to obtain and maintain intellectual property protection for its technology; developments in clinical trials or regulatory review of the NeuroStar System for additional indications; developments in regulation
in the U.S. and other applicable jurisdictions; the terms of the Company&#146;s credit facility; the Company&#146;s ability to successfully <FONT STYLE="white-space:nowrap">roll-out</FONT> the Company&#146;s Better Me Provider program on the planned
timeline; the Company&#146;s self-sustainability and existing cash balances; and the Company&#146;s ability to achieve cash flow break-even in the third quarter of 2025. For a discussion of these and other related risks, please refer to the
Company&#146;s recent filings with the SEC, which are available on the SEC&#146;s website at www.sec.gov, including, without limitation, the factors described under the heading &#147;Risk Factors&#148; in Neuronetics&#146; Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2023 and its </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2024, and Greenbrook&#146;s Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2023 and its Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2024, as each may be updated or
supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company&#146;s expectations and assumptions as of the date of this press release. Except as required by law, the
Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company&#146;s expectations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mike Vallie or Mark Klausner </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ICR Healthcare </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">443-213-0499</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ir@neuronetics.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EvolveMKD </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">646-517-4220</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NeuroStar@evolvemkd.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>d928209dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neuronetics Announces Pricing&nbsp;of&nbsp;$18 Million Underwritten Public Offering of Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MALVERN, PA., February&nbsp;7, 2025 &#150; Neuronetics, Inc. (NASDAQ: STIM) (the &#147;Company&#148;) today announced that it has priced its previously
announced underwritten public offering of its common stock, comprised of 8,000,000 shares of common stock at a public offering price of $2.25 per share, resulting in gross proceeds of approximately $18&nbsp;million, before deducting underwriting
discounts and commissions and other offering expenses payable by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has also granted to the underwriter a <FONT
STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an additional 1,200,000 shares of common stock at the public offering price per share, less underwriter discounts and commissions. All of the shares in the offering are being sold by
the Company. The Company currently intends to use the net proceeds of this offering for general corporate purposes, including but not limited to sales and marketing, research and development activities, financing of potential acquisitions or
establishment of healthcare practices, purchases of inventory, general and administrative matters, working capital and capital expenditures. The offering is expected to close on or about February&nbsp;10, 2025, subject to the satisfaction of
customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canaccord Genuity LLC is acting as sole bookrunner in connection with the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A shelf registration statement relating to the shares of common stock being sold in this offering was previously filed with the U.S. Securities and Exchange
Commission (the &#147;SEC&#148;) on November&nbsp;9, 2022 and was declared effective on November&nbsp;14, 2022. The offering is being made by means of a prospectus supplement and the accompanying prospectus that form part of the registration
statement. A final prospectus supplement relating to and describing the final terms of the offering will be filed with the SEC and will be available on the SEC&#146;s website located at http://www.sec.gov. When available, copies of the final
prospectus supplement can be obtained from Canaccord Genuity LLC, Attention: Syndication Department, One Post Office Square, Suite 3000, Boston, Massachusetts 02109, or by telephone at (617) <FONT STYLE="white-space:nowrap">371-3900,</FONT> or by
email at prospectus@cgf.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales
of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Neuronetics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neuronetics, Inc.
(&#147;Neuronetics&#148;) believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering
<FONT STYLE="white-space:nowrap">exceptional&nbsp;in-office&nbsp;treatments</FONT> that produce extraordinary results. NeuroStar Advanced Therapy (&#147;NeuroStar Therapy&#148;) is
<FONT STYLE="white-space:nowrap">a&nbsp;non-drug,&nbsp;noninvasive</FONT> treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the
NeuroStar Advanced Therapy System (the &#147;NeuroStar System&#148;) and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (&#147;Greenbrook&#148;) treatment centers across the United States, offering NeuroStar
Therapy for the treatment of major depressive disorder (&#147;MDD&#148;) and other mental health disorders. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NeuroStar Therapy is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms
for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also cleared by the U.S. Food
and Drug Administration, as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15 to 21 with MDD. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary
results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Safe harbor&#148; statement under the Private Securities Litigation Reform Act of 1995: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements in this press release, including the documents incorporated by reference herein, include &#147;forward-looking statements&#148; within the
meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws
and other applicable laws and &#147;forward-looking information&#148; within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute &#147;forward-looking statements&#148; within
the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as &#147;outlook,&#148; &#147;potential,&#148; &#147;believe,&#148; &#147;expect,&#148; &#147;plan,&#148;
&#147;anticipate,&#148; &#147;predict,&#148; &#147;may,&#148; &#147;will,&#148; &#147;could,&#148; &#147;would&#148; and &#147;should&#148; as well as the negative of these terms and similar expressions. These statements include those relating to
the contemplated public offering of common stock and the company&#146;s intended use of net proceeds from the offering. These statements are subject to significant risks and uncertainties and actual results could differ materially from those
projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to: market conditions
and the completion of the public offering on the anticipated terms or at all, including the satisfaction of customary closing conditions related to the public offering; the effect of the transaction with Greenbrook, on the Company&#146;s business
relationships, operating results and business generally; the Company&#146;s ability to execute its business strategy; the Company&#146;s ability to achieve or sustain profitable operations due to its history of losses; the Company&#146;s ability to
successfully complete the announced restructuring plans; the Company&#146;s reliance on the sale and use of the NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of the Company&#146;s salesforce; the Company&#146;s
ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using the Company&#146;s products; physician and patient demand for treatments using the Company&#146;s products; developments in competing
technologies and therapies for the indications that the Company&#146;s products treat; product defects; the Company&#146;s revenue has been concentrated among a small number of customers; the Company&#146;s ability to obtain and maintain
intellectual property protection for its technology; developments in clinical trials or regulatory review of the NeuroStar System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; the terms of the
Company&#146;s credit facility; the Company&#146;s ability to successfully <FONT STYLE="white-space:nowrap">roll-out</FONT> the Company&#146;s Better Me Provider program on the planned timeline; the Company&#146;s self-sustainability and existing
cash balances; and the Company&#146;s ability to achieve cash flow break-even in the third quarter of 2025. For a discussion of these and other related risks, please refer to the Company&#146;s recent filings with the SEC, which are available on the
SEC&#146;s website at www.sec.gov, including, without limitation, the factors described under the heading &#147;Risk Factors&#148; in Neuronetics&#146; Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2023 and its Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
quarter ended September&nbsp;30, 2024, and Greenbrook&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2023 and its Quarterly
Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2024, as each may be updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are
based on the Company&#146;s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a
result of new information, future events, or changes in the Company&#146;s expectations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mike Vallie or Mark Klausner </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ICR Healthcare </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">443-213-0499</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ir@neuronetics.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EvolveMKD </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">646-517-4220</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NeuroStar@evolvemkd.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>stim-20250207.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 2/8/2025 4:07:55 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:stim="http://www.neurostar.com/20250207"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.neurostar.com/20250207"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="stim-20250207_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="stim-20250207_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>stim-20250207_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 2/8/2025 4:07:55 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>stim-20250207_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 2/8/2025 4:07:55 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="stim-20250207.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g928209dsp1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g928209dsp1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MB2XC.Z,G<I +\@G SUZ&@#4_: U*TU3P_H4EG,LJ_:)2-IR2NW 8>QQP>XH
MT?BA?6D_P1TZ"&ZADF M,QI("PPHSP* .<U?Q)KNB_ SPLN@74D",'2\FMS\
M\7S$HI(Y7///'2@"S\6O['G^&NB3:1)]L?S(Y)KA9#,5!C(R[$G!+'OWSZ4
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MX8N-2N[!KF_AMXXIMDEN81@LAC4DL!D9W%L8[8H W* "@ H * "@ H * "@
@H * "@ H * "@ H * "@ H * "@ H * "@ H * /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g928209dsp1a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g928209dsp1a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M6A)!^@W#'ZT &R\\@ 3P>=G[WDG;CZ;OZT "I>")P\\!D/W&$) 'U&[G\Q0
M1)>+N\Z>%^/EV0E<'W^8YH 2)+U9 9KB!T[A(2I_/<?Y4 (([_S 3<VYCSR!
M P./KO\ Z4 $D=\9&,5S;JG8- Q(_'>/Y4 .F2\+YAG@1,='A+'/U#"@ D2\
M*((YX%8#YRT)()]AN&/UH "EYY  G@$V>6\D[2/IN_K0 *EX(7#3P&7^%A"0
M!]1NY_,4 $27B[_-G@;CY=L)7!]_F.?TH 2%+U9 9KB!T[A(2I_,L?Y4 (L=
M^) 7N;<QYY @8''UW_TH M4 5;G4+6SF2*>79(Z/(HP3E5^\>/3(_.@"O%KV
MFS(K)<'!E$'S1LN'., Y'&=PZ^HH L17T%S#/);.)!$2I."%R/?'/U% &)'X
MM671M-O%M"+F\N$MWMR_^I<N%;<<=%)].<CUH U9-=TJ%7+W\*A'$9^;^(@D
M#\<'\C0!7TW7[>ZL6FNI(X)$>160-G 65HU/X[: +EIJEC?RR16EU',T:JS;
M#D , 5.>G((- &;I_BBTNXFEG>*W'G"W\LL3(DN3^[=<<' S[Y].2 75UW2F
M!*ZA 0)#$3OXW X(_/B@!?[<TOSTA%]$97D\I54Y);!../93^1H M75W!96Y
MGN)-D8(&<$\GH !R: (/[7L!))&;E0\<@C92""&*[@/^^>?I0!%-K-O_ &+>
MZE9LMREJDA(!(!9,Y7./48H H6_B7S;BR#BU%O.KL\B3;A'MC5^> !]Z@#2;
M6M-2(RM>PJ@)!);&T@ G/I@$$Y]10!-!J%I=7,]O!<))-;G$JJ<E#Z&@"S0
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M6G2V5R56XNX4WQ%3O1CT!/'([T 9R:OJMG>Z5%?LIC!%O?.BC:)9 =G/8@A
M<#'[SZ4 :>JZZVF7K0?93,JVCW)*$EOE95QMQ_M9S['B@"B/%VW[UF&53<AS
M')G/D@'*<<YS[8.>M #Y_$TUK;3O+;0%X#"6*3$Q[)#UW;>",$G.!C!SS0!>
MOM5NHK>26QLQ)Y3%&%R7AW'@ )\AW9)QGI0!6F\12PWEQ:O:!'BDBB^9FXW@
MX<_+PF00"">1SB@"O9^+Q>2Z<!8M&MWY0PS<_.C,"O&&4;2"?QH Z>@ H *
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?HJ*,*HP!Z"@!: "@ H * "@ H * "@ H * "@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46315446267328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001227636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  07,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEURONETICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-1051425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3222 Phoenixville Pike<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Malvern<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(610)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">640-4202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock ($0.01 par value)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">STIM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MU\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK
M>MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ
M!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.
M\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( )B11UH'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ F)%'6N.RL8+O    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ F)%'6IE<G",0!@  G"<  !,
M     ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "8D4=:
M*7(GKDP$  "%$   &               @($."   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ F)%'6I^@&_"Q @  X@P   T
M     ( !D P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "8D4=:EXJ[',
M   3 @  "P              @ %L#P  7W)E;',O+G)E;'-02P$"% ,4
M" "8D4=:'#AEZC\!   \ @  #P              @ %5$   >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ F)%'6B0>FZ*M    ^ $  !H
M ( !P1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
MF)%'6F60>9(9 0  SP,  !,              ( !IA(  %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&      D "0 ^ @  \!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d928209d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d928209d8k.htm">d928209d8k.htm</File>
    <File>stim-20250207.xsd</File>
    <File>stim-20250207_lab.xml</File>
    <File>stim-20250207_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d928209d8k.htm": {
   "nsprefix": "stim",
   "nsuri": "http://www.neurostar.com/20250207",
   "dts": {
    "inline": {
     "local": [
      "d928209d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "stim-20250207.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "stim-20250207_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "stim-20250207_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-02-07_to_2025-02-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d928209d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-02-07_to_2025-02-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d928209d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.neurostar.com//20250207/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001193125-25-022833-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-022833-xbrl.zip
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M^V$3TZMC6LW)D'OH&+@"+Q$RWP4U" 5HPCCR0NHS$2EO2A18EAI.]0CQ V(
M_#+06IBA,P7$"/H!%?.GR;TA0%LQP>>PY, QI5"ME;IT^%3@O55@G:+I&<)>
MA/)S4'^C6%Q8BJ%_/ED?LE 7USC'_T@>@OPP98O\..E1SZX2#83P!A1D%X*F
M91WH,?*_>52OGRSZS\>%8C.OC!Z0O.C)L[WDPF QKX Y66:1(+/:=Q6!.M7M
M1JS*87Y]#9?5]JTCTOEX1>Q:M0P-#XP;V"BS?-/OQ^MW'WRW ]SW;[Z XP/O
MY^U.N9O?LW+/& 5=&TXM:O:#$<*JTY)E)T%B9@2YE>7$!![LS:Y7RZ;'@PR\
M>K.6G5G+I608"7!GIMY/@X%=7@R'3P#-FUI-H_H]6\V#*@P<+3D9EB:F\5 ,
MV<#2W)*]/SC8KJV9/M^L[36LK:=4Q.2+V)SU9G-/LKD:*]7WG>W:7-SGQC:W
M]10Q U!-+L8D9'/!RCULZ"&2! VFNSH?^_970H[?-C \JJ2[07EDQ0P6M'_Y
M5JL--S99>27?RA[D:WQ#RFPK=$;$\:A2J2T^IZ+\9)Y]<PR2% U0KY+VIV-H
M1O;5P1N/LH.?ZVJI;W2(Q4'!K-G[!(P OIWYV+RK_U8V'ZW,I$V8F%KV0)O*
MT\OH#;O01N #+.F'PKDE^S]5RU6+!%22.^I%;*'Z_U++.JOF'JN^T?IG3+P&
MT?:Z]^5;FUXBV@3%/&DCZSSX1.U?V"36J(,? =QP3I5+OY)/G@!\2KY0><O"
MI5QY,134\UU$AHP,IL3117/H\19LEND].'.5:JX(0#M ESCH#;F18A*.$& &
M6+VFBKALR'VS#=;4!*N-!#/-%03-/GO]8L"&*-0>E-(2RV*?RS;QSZ^_;'M!
M*:-L>J6CT.XN9\TO[XZM)F0=ZU?$DX<_Z6<[YM'=94.--=G0+MD&2C=<HT:X
M +M4)_G"PLD(-(YY@-)!XWRA,7NDF&X%#(N79_"%=:Y77LSKI,@@/98WQ<$G
M'(9&[?6!/K@CV1U7\!SH,?4=+ =2Q\&=I-@87UUWJ72569AQUR8,M7V:)@Q9
M[2S'VI R?P=+IW^3=U#-0F&\7+BWMUPEV7A!(_&K#)88,) Y8 EO0J>J8-XF
MV#L=I; #$B@A6^^:^K^39#;!?39)<CQ&)4:DD4Y']AY8C]WNV\5[\W6CWRZN
M/G2O2IV+SY_/+OO=5O+A6ZX;6=:&A:/UNTQZ(1OC[HVJ=0*:;6VZ ^;%"SCK
M<+,9O8O;TW$A61!*DG4:\@%#*->[?,YN)-.EG#)Y3'WD<!L^^L(G2]_A*D*C
M2 J? 7-5D?1\ITSVT<6A3.SJ22>->+9MG1P0;0\:$> T??('%H\FTBRYI!/,
M=;&\2=JC]M@=ZJ-?EB[YQ/P(@B?Y_+E31 @B62"9@@=HO%-*.^ HZ9-)I0.O
MQBAXLHL+Z,/,L$=H&%+\"A^1# A>2A:3"2W%G/LWB0X^T4D0$1*OMPAPK'+"
M_$$]P9[(<1$\'?XC:D2!W-Q '[D<D[[^/IUT/(T,=_7N)<?D$PKSB>(LDR!Q
M9H$'0& _9'\FG33_F$V"AJ"  41^AJ3B.$$T\ "AP*@_V66[D>TI0Z@NUX*0
MDI[*1KJZ!^#26"5D+Y=H,<>K&PSIAO4DPVK4&1%@6"WB_C?I<*4=(<?$4GAZ
MDPY\AJF'9B+050C*K,,\36(^T%&K$A?</QE*,=:#N/'[E&L)%"AAB-T*A8?;
M@#24 #.UBG9>@M!3/KO+,DI/()9I,6:7UH90W!BDK;5:[TF92=\P*.YC3B%@
MJCE!&4D8*9;U&ZX)8]E] +A$Z>:)Q'!BCB>4SMKS=FY5$T-7T>!_\&2B$V9;
M"W6272Q.!&H';F:J>\). :D:_J@R.0,M-R2C>')CHQH-F,93X!<1Y67TH+SF
M73_S7NUS/5N.-WB\"^@!<B?F*'@V1'<.&*Y*IIXT3W4GF0NHW!"5%)!@Y&CE
MB;*:Y'*EL:/2LG;2%P3,=3*X.Q,?RLI7*/D)!P8.XOU+][J=-R4_68=E0.Y&
M4C ]#V6Q#YK^DW5</F[6\C=F.QDUS5DE/%BA(S,$G>/#PL2U>=TPGTFPA>2=
M#%1'^*3IGXT]B$*-SCT^YF&\88IZS/!@K'-@S4GTVA1L37_OLCOFB4#'!E2Y
M.YWE%1-8CENJAB00>&J3P>A?(VY@OD*/ *P%+\'52'< 34>,>N'(0=4+)';H
M8&^);6OKY3Z^3RTD9"#)Q) 2ZHXA'F/&H>,)" )C" A(R%NM]#3@8=PV^:S%
M"*80P9QVK]"94$V.B@L.%'AOWDW-:C+.%^0=>]34#QI/FW-[>D-:!,I(QZC*
M2<N<-KV,T::ZQU7L/\;49;D0C&%,X-NX8:3 ?P6!%SMR5]O94D23\]27L\?[
MZ>.S2#GD'G23^NI^M[/H0)-NM?+X.GW4/->V@!S-D*B]#F;L"DF'&#:_/5 S
M6;]]:#39WW#/8K]4*R;%$@!%=&RRX7W]5M*#3Y^+LIE+K58KV8>'A];10=J=
MRQR/(J1C( _'@"Q\8^B.X3;C.(C4-1/LEU&,%9@2"R<4TI),I,J"0W 58,54
M(N[@+''1X ,H.NP\X#+"])1($G]ER@AIQQQ(&/NS%ZAF&SZ7=C5GHUEWB?UZ
MG ZX9PI;*[?4Q16T8D:^QJEO/LF80P8,K\9!9 )HV!B;\"$*(8F)IT<R5(1>
M.VVM>65NF/?B'6U^9G#=%<1]%O>#HP[ W0YYJOMH!T@K!HI<SV9ZF,O?"!U>
MF7(D#[+;:E=,(.&YK@89"&-FS\:!1\,$\0,4<06,C.%*3U!JKP)A6!>,6&@@
M/%<9;%347WV-(+/+G@" @0E2B"G F^+,A^K#W1[ G":-@#&,LZ%8VQSQ ?#'
M*EL&D<#-3B0ESBP^'61CQY#9S!Q/9?9.)=-@+#VECB!+N+][&SX#]@;I[F>/
MW4 (%0%$72/7WZ@'#L<E_8".).1YEX@50&HQCDV?P2PP[@/3+3QETF1<U$L#
MW')(6ES*[L:WP>ZY4Z>>L]WHK6R$9:/C[[ML=*'SQ2Z"5?4M%(8.DWPQ&^1T
MO</5> Q?8P-[92:']@%$.DE*XE&X&*60<I94@:FLPE5/&0>SXCAGR Y4AFX"
MSM((G>M#Z3PUK0C-_((BS29X!J01/MC$E(IT_A(8/.2MSV*/=_ N4Z'=H9$N
M30 8.8>\"#S5#3A-G#5XJ@GZS\]"Z(REG\!)M8;*K>C*]1+7^:#+3!90T,&:
M3^!$S8<$T:6OXYB9E;QX9FHV,XVL(:43'N#3-,U'L*2B<1 #(\G5K8$EH"Q@
M^- W(H]RPK)E'1NDQHHZKT45R>>VQ6Q;':9,RJO?14HSJ#2Q-HDWKC<MEA8T
M8(&.L62"L"TF4 >Y&(]DD,^LO!)C'41\^-XH]AZ9%&]U/A\CQ^7\6 BW\U!V
MEID9YJ0)M$GO,X6AG/6F94R#=J>Z*I4 K5R_,,TAA BI@YDN+18QS<=ZG^=I
M!#S!LBJB3NT=S41<!C/P4N9B51 G@']C #!/B'E=2^4RO"PXC\'=F>\#WGN&
M1EO51*5!A1-MQO'P,#5B<K4/S,ED5#5+N[^:@1&&C']%^I0I0-+/HN1?2RGY
M:CJ/B>FS(,Q28XJ$]50#EN;-6JE \]SX_+DTX2!\C/1BTHX%12%C>W5$Y&$5
M!=45OD<>@U>-/%.9<CFJ@Q&F$SL58S]QHH7$I)J]QC?,I3W;\E%QSJSGO(&'
M G[16Y-0T30$S8K2RT#GDD%3"20VJ?/%D-[J-";[XJ$NZF"U& :, CV0KFFN
M\:$"T2DNL.O5<>ZG![\7S>&#NM;F< GB-:>ZJ[@>^M!4GLC@A*MF 3>S.+Q'
M]M[6A]^ _AS0;W[?0/]CN@4E@]C0W!,@^@KH?Q_/&<T*0%/M,B<^DZFEW0_N
M"BFT$S*S5KL\K[5WO&-^.^:PP9;YO3VS:5[_<2OQWTVVN3=6;'-OOMPV]RWM
M8=_(4C;8^DR2G]@P/S]2&GC"N=WZUN582?5F97-0QA.V=C_N*)UE\6Z7_-.F
M4D+3>!;W\)S#M-Z:=SRQVB^Q[ 4E2PZF@!N5E7< H:%9^^\+]FL>4KE,4'KS
M7O/$*EN[T1$8%T(<)>;71]RF#9&LZ;)[RRJ/0NAL5=78+' 9(+FB;C(P"=N
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MK:3SUGA9,A:/I7&-L9QYK8";\3'[AU^T.(#))>> OL/Q"]I1(N%=%#9)1\$
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M-JZUAQ; > *FWA">BRL,]N=YDDO_Y0/T!G .D+[ !8S(P0ZX4=]$D:3[NZB
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ML=.2DXU+9DAQF<YPH.C/$U6*N;135#];0B?B-R@0HX,\G8&XA7>>&?#)0XF
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M4 L.Z2^K-U8Q,'R),VAOQ)TP:$&]0VDZ0:;SNC+]K^]5_H1^>[C"O*-).4I
MWSYX_6F6KLQ5*<3;4U/N(:BBL]G*)#,W(G3]K8(M9()#1PBA-\C5'\P#<_N^
M"5;C$IF?H_;\3TG,\636DZ!G6[89(%#DW+%"^(/ 90R4JNVEI[9JZ]STG4T*
M??NU6WZ^&218#T$7V^H=;D1LN2EEQ+*Q-TV#7K:M&$^/8-L(NE>45OGTGO%
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M.*I70;C?^9KNK)>R"?[+[PS^J?T+CK43X&$AJ/Y?)Q\@2%%!TC*) $Q[03(
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M4H]Q)T96\UFBXDD.->9#OUS5QY2.JR-GDA$K6Y@:]8[2AKG(49R$NVYH#_L
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MYZJA)QX7#F9&I[Z0I/Z4RGK,5E?2%6&$T9:=N[I\+ V]<)7@I%DI_*RND6"
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M(XU/0BU+_@HA*-EV!U:)XJ"Z!)3Y'4*,C"\?CY_,6.$R8';M(^C],P$EO:
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M2D?0GLB'5[K0H]WT]D*_HAR04,UQC\6_&,2JGJ?0LV_^_]5><;?W]\/8Q0.
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M%OXO=E'V\*V7+3_UT8S+Z<MDI=^3FHXC0)B>(-8R=#V/RP9Z8N"G"-,M[=5
MRY'R_R+\0T8=@^YSPDJ82-.R_I)DPU*7%W-?QA:X]B/-VHRGZFNI8"&:C4%&
MR.#)P"-$@@P(]0S@7&FZ5L&I8\0*0BA-&<)Q=*%!'$<7*3^+0X2)/E;VR#@8
M6VP&K*8%9(+-NI6II-\(0;:R=%+X]R-LY$0XB:ES$,A=$" %,XP<' ;OQ:[+
M-]KDZWW7 ;:&C<S4Z@A@+C#K<P5KIJ6E XFC:D8,A*TQ4N)0V98X3A%F49>K
M^YXW3/,=  %!5'O)7Q+>/ZD[)UXL ST+9&V.!L^EI*958B_,!L0'UJ&Y::Y$
MJ%>KX0=GZ56RLMY+T*/%[:7M/\\FKCT_\Z'O1-IJU"] E)?CE@-I.K:@*]0N
MT WEJ;D/4-/\NX&64EQ2F$^%".(:SJ-KS*E="T?CK#!>O/SN8)0U9FF='JA@
MA@R7=5@2I"U)2YU/D<?@\,*QB$0.!+Z/EJ)60X)W9?4)'G)[%LUR;@A-H!S;
M87X*(D-'PVT^_!.=B:!765CL%3LMPSW,.*H7K8.J7M9Y5/4#"5OL*8^>[G%H
M;1>HXE!Q+B\-2Q^AS0RY- ?X[MO:#X(#'F+?VJ'!*D^K8B#P1SD1%80* I%(
M$3^: 31@FB?F(D$,#B/KC/RM9)!9GP!GS4&>P6G&SXE"&_$U%(3C!'E^X8L(
MI$$_(-0>0JT654]*O<V:V75>$&\30"-(=.?YA84XY0MD"#\##)?R-$=L"IBQ
M@@E2RP6M4]"+7I4GQ6%!("BR5$EKI>150A+1UO:1NTXS2:3V4[I(^6S049IY
MC?!C\*8=8,L^*MU>"RQ XR[/7C;8X<B/[:$D<%.F94XM43<<<MA78]V<Y81S
M"*\PAM4 IB3$7M"Z"_CLN6"/7[*+%BAH$1:_$9WR;=8J6:/@S!"" AV8H<5-
M]9B:T9K@'QC-"M@^5,#D-!/^\L4:$9S3W>\_,$<N2X2A$B;RIE:<<]ZUP6;[
M)YN@]3C,NN*F]P!!];&<PM&R9 2>(F^[ &!GD7T=-X<O/SUMR%@WWF=_V5!M
MI%AWOHK&X@%6- (R*-#]'9K+&)#J$>$Q.2Z.\$Z _]:OY@@]+>3B.G+Q$ 6#
M[^UIU=2.6K=-@1"R5F@%Q#\JC-H?(E YO3KRU5>4%(K$H!<B=D,B]H!E3/&[
MI6CIL2><DJ5J),FQ<0R$%X,$T]K3!'1-UB5SVQ%G-M@60G9'GBU^R,"E'&#E
M+S"X\K?+,3_;!:*RV)&Q()[)2J9AJ)//D*]]NK;IP= Z.'ME96\1P&G_Q<8&
MH3L3+E=O<9!N^R"=/<QS),<F34YS:.,S?["AOPHD9H6E.*^)NV!*8&\]=X0$
M9Q8XL/Z- 6_'^B2^G];976G#A:3=B*0]1$%#$G8"G^4<$H=H05):GR/G".$!
M^Y4QD*,I*BVAS&U"LFNE;1[+82&%MRN%#]%N@$M\DKM(,$)4NSB7=N 1R'5(
M,I4Q;JX*B9G[&6ARII"@K1C)/+.XF="#-2S.RFH@H7'P_'L4E,2$"+#+$;4<
M&AO3$@T4  A&/F>(PJG,B<5(+T,Q%M_[:EF 6Q5^C$;]Y:7_(8J_)]^)]=PA
MD%8-&0$569>KA'.^E.+';"[V_6<^W#1"#6=^^/XT&Q+X![+B.=,@")T!/20=
MI.T3X9+<9FLZX(14Q^ZL%,3R([-GE42L6WDL.%+9%R+>%'!^_J<(F6_X\UX*
MD0VJQ\@Q92[19[*$' 47(ICK%5M>NFS)PJ$6-5.UF^,/M"WI'"D&@HRM\M,,
M(<DM4Q=ENU1>QO)1MYE3";X\G*?Y.T.9NVE30K2U38P)C6.!:7,Z0V*&F-:#
M?$>P+Y2.R=&V- ^SJDWE-5)F'4,Z;TI/E UJ-NL!#85\W-BGE!>!=(KY/TT8
M%@9D)5+;2P,1DR5F\5*9Y^(HY4"QVSB<'/QU>6F^(5*:!LZ"PAO?7/N[C*)L
MIC8VVQY">!K8'J^;ZJS (T0N;&]AT=RZ3G^(2AV/"I0&C'-,Y0V:>EH:XY=2
MW>H02:2C))3KS,^%5A&.1J3V,"8YY+C1YEA>HIJ 6O'J3$^(-@(LO@3+ C#]
MO9#%6XTF?'V DCA?_FN>K,"-%Z0&UUQ*%]O*5^$VIJL+BONP>M(*N;DI0-+A
M?\^(Z@#$//4O X7@+K37_N&"*#@FG\US+MJOA!Y/_<XGP<OTK9KG4I*A,.P?
M:Q_:QJ+][#I"O;QD"^X\;!$NX"N;L:W90]3R+@+@E?_,/ 8,W05RB>(X+A.P
M<)BN >I T'&@<+,'.])_!NS([;(_6_*W-9BB\/=?;#S5X>AV(9[^2:N&U3*,
M5#D7\I65^Q =$G,L&V,*5Q ,FND!' %KV[L2C4>D%HFM&HTLC#)I@Q@Y(]B/
M=\SQL&*'H[(<@I^0556104&MC22H% ;&$X92U0JJ!2U'8_*74S8@CXJJ!K^A
MJ8OQW1>*[3JTFG1699ABMYA,1A= V]OJ!%B8 G^RX@"F3K*EN;HPMZ9B,W"/
M GLA<,9L+@&N"ZARGHR --+5]=9<SR9%A,IGRK\6-75E6/])%_G$+9.42PS5
M<[(J[Z@&5>6?075HNQI43(_ ZD"E$SDL>%#\XKE(/&!Y26E471.-CY753^U0
MN=X>"!FYQ-H9(^-2NDVDN%^S$<WU+'<KV$MICD+OEI[?W]EN-:144C*I8Z?-
M]*2L2#Y<R2"EIJPS(V624\<)RFT$EF1N2DT?::2X/?7<;BZ=9)HU=*HB%T\J
M:X&;X"]F)0L$C$+!G=3Y_N6EF0.@)A0+"38IJDR7MGY;U1WN<SZAZ@UX)X_;
MWJ[1JU[>J6_J10707[("Z"0/ZZRS9-Q(AJZC7\;88WE=0T8/L](7?F-.;>2Z
M/B)[<YI]124# 35D.BR-ZCKF5 FJ0!C!&>&&J*QT9NZ-X36OG]0J\S0Y*<^!
M%8"=2750YCX?I >Z[%&]AJ1I!J,\J]""'2)%$K:*D/%53HV-)>EYRQ&.!:U\
M>*5>FFS\HAHTIQ!UA#:2 -;/*"BR_1<AQ;]D==5)K!'.G>7NGC=I+(CVBO&Y
M+"<Y)(FJ+[GQ_8Z0-$YJDFTE=5FEPMC7ZCBK;6T4=0&5V)U>!6'RF:UYL8)G
MVW085'6[AJFRHA /F%H5#P'K"&*IHKDN9F/"7;4@WG.^PWE<YH)[JN?Z3O,L
M.2%J-59!>HR2+H*6+C,9><7%+ .TXR4+[?17+%GSY*'3F@@8!KND%Q(<8WTR
MO4HU:PH8;Z&\8)I!_BD_>9'K^$O6LTE!I%%9]8FH*BI)IA[UE(F;;=H;K,=D
M)?.<W;T1<*0%"!.@-,G:1<<9Z7"A6S#'N$ QP!@#ZVQD\(578P'PI=Y>?^UP
M\TE_9=!;Z?=6BM[*FY[<+JY6.'#?8G<;N+?9R&6FYZE5D"M%&]WD(R>P"EWW
M)4:'K^/)9@2H8-\#5STR[QZJ#02SHEV2#5=4/?<=%4A#12&HG'$2,"QQ2S:!
M==>SVMWE$)IWXJ(B6D =_V?"ZGZZR"'=<%B?ZW\RQ5D=- MJ_ESDQ)7[&"H:
MIX+[@#WW%890*<BVO,11N_]0*>,P'QA+%HK%'##''%>[-&,']0J.6]V<];.B
M'-G"*]A.:=YN4V;?:2?F0:!C&'+&5CE3I-3&MZ,6M/%2S!X![WMYCC@.0Q4-
M!8 BAT#1)H_'1Z8)42B#MC!ZJP,$Q@$=76AB@F$Y:.C>4:WX7O F']=-10VW
M9T:2AS NK#\Y@H)8IS3]O=B"R+>=!W.IFTUE%,"2T3,$G\3]"RX 1$95%"C2
M82/WT/*2D$/;4)&%-:HA"0G?KZG2'#,,%&MMU:+'7G+_> WT9R@FL]+C-TES
MBJ$QKS?3&""\BYC!N67$CBT<A)!R=.ZQA1XM$QUX8Q/"DSAS5E=<H9#3',:1
M+M"^:2>OL=!R:L0LK[FD @HL,2A8E0",Y&QPYZ/K<J2\DW?./I-YPG/S^P'U
M%4!AXJS<D%=F"%]#LZAVZ04C#)P]PKH\S[?H\1JZ=0:MY+X"P4BQ#289.1H4
M>Q]Z<"J\@IZ7 ^ KY6B(%J)*<F!HR:V[C:R$U:9@*+S+#ZO&G%WZ^OIS0EQ]
MD+(<"(NY'Y:74-]15?!LP%)83I8A+T_E%@=22:,";SY6#NW[XFY7I*6_T<D8
M9<5I*NV)D(6[D- (*NS*"*8-0V//@6H?\)YHS_8Q/(9 GLAHQNNT:J(83W1A
M@"5IBSNFG%V%P?]>5E^T]8G-#>06<>8K&XL:-\H5B 7X5'/LK?6T]DU]#>Q7
MM+I\.BSG93]T N8?KDO O/X@")B#!7OSZ>#@T\]MWMLKT.A>O7SJ5]"J1L3-
M!7A1&K<TO43&DMD#Z =2=J]$S:&7M%<5F/,"2ETX6#]B7\8\G&Z/C+'YY2S&
M2XD.72IULSE]YQ9>#EJ@M]AW3V7V@COD$[U$/-R[AW SBD2O/P4G?]Y9MD0'
M=\F2 M_VM.?C+[]JC%#?WNO?POD8'KP]*L>'94%,5T(HHFQN,L@FV0"]I2.I
MVZ_YB^#T\A^-^V=K_!G.(,]3 L\;FSO57.E'%(Z4SA!?'RU;5D$*F#S&J,_F
M[*C//[]_\^GM[^;#'P]^_O#Z_P%02P,$%     @ F)%'6OV;)MZ6"   UQ@
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MO6'_H >$!3RD;'[<6TG/EP&E/9")ST(_XHP<]S9$]CY^>/WJ_7>>!Z?G%Y_
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M)#A3<4C5L6Z>M--O&=(F3;N!^H>@24+8A,?QBN4W9:0MK17)'2%;;X77!+G
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M.R[5EOZ]$_DNFOWV!;7G/U!+ P04    " "8D4=:TG%88K,$  !]*@  %0
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MY/J(?;)W 6++WU!+ 0(4 Q0    ( )B11UHZ=!W,HQ4  $J    .
M      "  0    !D.3(X,C Y9#AK+FAT;5!+ 0(4 Q0    ( )B11UI8EM_9
MK)\  %LC P 0              "  <\5  !D.3(X,C Y9&5X,3$N:'1M4$L!
M A0#%     @ F)%'6OV;)MZ6"   UQ@  !               ( !J;4  &0Y
M,C@R,#ED97@U,2YH=&U02P$"% ,4    " "8D4=:F=ZN,V .  #L+   $0
M            @ %MO@  9#DR.#(P.61E>#DY,2YH=&U02P$"% ,4    " "8
MD4=:$BN^D[@/  "P,0  $0              @ '\S   9#DR.#(P.61E>#DY
M,BYH=&U02P$"% ,4    " "8D4=:EQ*U(CT#  !."P  $0
M@ 'CW   <W1I;2TR,#(U,#(P-RYX<V102P$"% ,4    " "8D4=:NI[N7UL&
M  "]0P  %0              @ %/X   <W1I;2TR,#(U,#(P-U]L86(N>&UL
M4$L! A0#%     @ F)%'6M)Q6&*S!   ?2H  !4              ( !W>8
L '-T:6TM,C R-3 R,#=?<')E+GAM;%!+!08     "  ( /L!  ##ZP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>d928209d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="stim-20250207.xsd" xlink:type="simple"/>
    <context id="duration_2025-02-07_to_2025-02-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001227636</identifier>
        </entity>
        <period>
            <startDate>2025-02-07</startDate>
            <endDate>2025-02-07</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-325">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-02-07_to_2025-02-07"
      id="Hidden_dei_EntityCentralIndexKey">0001227636</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-336">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-337">2025-02-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-338">NEURONETICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-339">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-340">001-38546</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-341">33-1051425</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-342">3222 Phoenixville Pike</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-343">Malvern</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-344">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-345">19355</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-346">(610)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-347">640-4202</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-348">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-349">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-350">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-351">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-352">Common Stock ($0.01 par value)</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-353">STIM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-354">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-02-07_to_2025-02-07" id="ixv-355">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
